PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
22204827-6	2012	IFNalpha-induced BCL-6 mRNA down-regulation does not require de novo protein synthesis and is specifically inhibited by piceatannol.	3,3',4,5'-tetrahydroxystilbene	120-131	BCL6 transcription repressor	Homo sapiens	17-22
22544395-0	2012	TGF-beta and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells.	Tretinoin	13-26	BCL6 transcription repressor	Homo sapiens	70-75
22124122-6	2012	Wnt5a and calcium ionophore activate NFATc1, NFATc2, NF-kappaB, and B cell lymphoma 6 (BCL-6) promptly and upregulate CD40 expression in GC B and Ramos cells, whereas p53 and JNK are not upregulated or activated.	Calcium	10-17	BCL6 transcription repressor	Homo sapiens	68-85
22124122-6	2012	Wnt5a and calcium ionophore activate NFATc1, NFATc2, NF-kappaB, and B cell lymphoma 6 (BCL-6) promptly and upregulate CD40 expression in GC B and Ramos cells, whereas p53 and JNK are not upregulated or activated.	Calcium	10-17	BCL6 transcription repressor	Homo sapiens	87-92
22124122-7	2012	Cyclosporine A inhibits the Wnt5a and calcium-induced activation of NF-kappaB and BCL-6 in Ramos cells, supporting a role of beta-catenin-independent Wnt/Ca(2+)/NFAT/NF-kappaB-BCL-6 signaling.	Cyclosporine	0-14	BCL6 transcription repressor	Homo sapiens	82-87
22124122-7	2012	Cyclosporine A inhibits the Wnt5a and calcium-induced activation of NF-kappaB and BCL-6 in Ramos cells, supporting a role of beta-catenin-independent Wnt/Ca(2+)/NFAT/NF-kappaB-BCL-6 signaling.	Cyclosporine	0-14	BCL6 transcription repressor	Homo sapiens	176-181
22124122-7	2012	Cyclosporine A inhibits the Wnt5a and calcium-induced activation of NF-kappaB and BCL-6 in Ramos cells, supporting a role of beta-catenin-independent Wnt/Ca(2+)/NFAT/NF-kappaB-BCL-6 signaling.	Calcium	38-45	BCL6 transcription repressor	Homo sapiens	82-87
22124122-7	2012	Cyclosporine A inhibits the Wnt5a and calcium-induced activation of NF-kappaB and BCL-6 in Ramos cells, supporting a role of beta-catenin-independent Wnt/Ca(2+)/NFAT/NF-kappaB-BCL-6 signaling.	Calcium	38-45	BCL6 transcription repressor	Homo sapiens	176-181
23049957-0	2012	Inhibition of doxorubicin-induced senescence by PPARdelta activation agonists in cardiac muscle cells: cooperation between PPARdelta and Bcl6.	Doxorubicin	14-25	BCL6 transcription repressor	Homo sapiens	137-141
23049957-5	2012	Low doses of doxorubicin increase the expression of PPARdelta that sequesters Bcl6, thus preventing it from exerting its anti-senescent effects.	Doxorubicin	13-24	BCL6 transcription repressor	Homo sapiens	78-82
23049957-6	2012	We also found that L-165041, a specific PPARdelta activator, is highly effective in protecting cardiomyocytes from doxorubicin-induced senescence through a Bcl6 related mechanism.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	19-27	BCL6 transcription repressor	Homo sapiens	156-160
23049957-6	2012	We also found that L-165041, a specific PPARdelta activator, is highly effective in protecting cardiomyocytes from doxorubicin-induced senescence through a Bcl6 related mechanism.	Doxorubicin	115-126	BCL6 transcription repressor	Homo sapiens	156-160
23049957-7	2012	In fact, L-165041 increases Bcl6 expression via p38, JNK and Akt activation, and at the same time it induces the release of Bcl6 from PPARdelta, thereby enabling Bcl6 to bind to its target genes.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	9-17	BCL6 transcription repressor	Homo sapiens	28-32
23049957-7	2012	In fact, L-165041 increases Bcl6 expression via p38, JNK and Akt activation, and at the same time it induces the release of Bcl6 from PPARdelta, thereby enabling Bcl6 to bind to its target genes.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	9-17	BCL6 transcription repressor	Homo sapiens	124-128
23049957-7	2012	In fact, L-165041 increases Bcl6 expression via p38, JNK and Akt activation, and at the same time it induces the release of Bcl6 from PPARdelta, thereby enabling Bcl6 to bind to its target genes.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	9-17	BCL6 transcription repressor	Homo sapiens	124-128
21156254-4	2010	Here we report two cases of THL with MYC, BCL2, and BCL6 rearrangements and t(3;8)(q27;q24) diagnosed in one center in the last two years.	Orlistat	28-31	BCL6 transcription repressor	Homo sapiens	52-56
21190961-5	2011	BCL-6 decreased Fas and inducible nitric oxide synthase expression and nitric oxide production, but it inhibited the expression of the antiapoptotic proteins Bcl-2 and JunB while increasing the expression of the proapoptotic death protein 5.	ammonium ferrous sulfate	16-19	BCL6 transcription repressor	Homo sapiens	0-5
21190961-5	2011	BCL-6 decreased Fas and inducible nitric oxide synthase expression and nitric oxide production, but it inhibited the expression of the antiapoptotic proteins Bcl-2 and JunB while increasing the expression of the proapoptotic death protein 5.	nitric	34-40	BCL6 transcription repressor	Homo sapiens	0-5
21190961-5	2011	BCL-6 decreased Fas and inducible nitric oxide synthase expression and nitric oxide production, but it inhibited the expression of the antiapoptotic proteins Bcl-2 and JunB while increasing the expression of the proapoptotic death protein 5.	Nitric Oxide	34-46	BCL6 transcription repressor	Homo sapiens	0-5
21041953-6	2010	Induction of p300 and BAT3 was required for the antilymphoma effects of RI-BPI, since specific blockade of either protein rescued human DLBCL cell lines from the BCL6 inhibitor.	ri-bpi	72-78	BCL6 transcription repressor	Homo sapiens	162-166
20630860-9	2010	Trichostatin A stimulation of RGS4 promoter activity, accompanied by increased binding of NF-YA and decreased binding of Bcl6 to the promoter, was abolished by mutation of the ICE and enhanced by mutation of the Bcl6 site.	trichostatin A	0-14	BCL6 transcription repressor	Homo sapiens	121-125
20630860-9	2010	Trichostatin A stimulation of RGS4 promoter activity, accompanied by increased binding of NF-YA and decreased binding of Bcl6 to the promoter, was abolished by mutation of the ICE and enhanced by mutation of the Bcl6 site.	trichostatin A	0-14	BCL6 transcription repressor	Homo sapiens	212-216
21083459-5	2010	The current study demonstrates that HSP90 forms a complex with BCL6, and inhibition of HSP90 with the drug PU-H71 selectively kills BCL6-positive DLBCL in animal models.	9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-	107-113	BCL6 transcription repressor	Homo sapiens	63-67
20501401-7	2010	The expression of apoptotic protein Bcl-6 and Bim were significantly higher in PI3K p85alpha/RNAi-LoVo cells treated with 5-FU than LoVo cells (P=0.000).	Fluorouracil	122-126	BCL6 transcription repressor	Homo sapiens	36-41
21083459-5	2010	The current study demonstrates that HSP90 forms a complex with BCL6, and inhibition of HSP90 with the drug PU-H71 selectively kills BCL6-positive DLBCL in animal models.	9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-	107-113	BCL6 transcription repressor	Homo sapiens	132-136
20124477-7	2010	Stat5 chromatin immunoprecipitation demonstrated physical interaction with a BCL6 gene regulatory region, and BCL6 transcript repression required histone deacetylase activity based on sensitivity to trichostatin A.	trichostatin A	199-213	BCL6 transcription repressor	Homo sapiens	110-114
27186084-6	2009	Epibatidine significantly (P < 0.05) upregulated CD38 at the transcriptional level and CD138 and Bcl-6 - at the translational levels.	epibatidine	0-11	BCL6 transcription repressor	Homo sapiens	100-105
19966776-0	2009	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.	purine	2-8	BCL6 transcription repressor	Homo sapiens	47-52
19966776-0	2009	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.	purine	2-8	BCL6 transcription repressor	Homo sapiens	92-97
19966776-7	2009	PU-H71 preferentially accumulated in lymphomas compared to normal tissues and selectively suppressed BCL-6-dependent DLBCLs in vivo, inducing reactivation of key BCL-6 target genes and apoptosis.	9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-	0-6	BCL6 transcription repressor	Homo sapiens	101-106
19966776-7	2009	PU-H71 preferentially accumulated in lymphomas compared to normal tissues and selectively suppressed BCL-6-dependent DLBCLs in vivo, inducing reactivation of key BCL-6 target genes and apoptosis.	9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-	0-6	BCL6 transcription repressor	Homo sapiens	162-167
19487462-8	2009	The mechanism of BCL-6 inhibition does not involve formation of a stable Rac1/BCL-6 complex and is independent of Rac-induced reactive oxygen species production or Jun NH(2)-terminal kinase activation.	Reactive Oxygen Species	126-149	BCL6 transcription repressor	Homo sapiens	17-22
19268365-3	2009	Bcl-6 expression is induced in Bcr-Abl expressing lymphoid cell lines by the tyrosine kinase inhibitor, imatinib.	Imatinib Mesylate	104-112	BCL6 transcription repressor	Homo sapiens	0-5
19268365-4	2009	We show that p38 MAPK mediates induction of Bcl-6 following inhibition of Bcr-Abl by imatinib.	Imatinib Mesylate	85-93	BCL6 transcription repressor	Homo sapiens	44-49
18927431-2	2009	BCL6 lymphomagenic activity is dependent on its ability to recruit corepressor proteins to a unique binding site on its N-terminal BTB domain.	btb	131-134	BCL6 transcription repressor	Homo sapiens	0-4
18927431-4	2009	Shortening and conversion of this peptide to D-amino acid and retro configuration as well as the addition of a fusogenic motif yielded a far more potent and stable BCL6 inhibitor that still retained the specificity of the original SMRT fragment.	d-amino acid	45-57	BCL6 transcription repressor	Homo sapiens	164-168
18256039-5	2008	While both Bach2 and Bcl6 possess the BTB domain which mediates protein-protein interactions, they interacted in a BTB-independent manner.	btb	38-41	BCL6 transcription repressor	Homo sapiens	21-25
19337254-3	2009	Treatment with TPA resulted in BCL6 degradation and cyclin D2 upregulation.	Tetradecanoylphorbol Acetate	15-18	BCL6 transcription repressor	Homo sapiens	31-35
19816083-10	2009	BCL-6 was significantly reduced both in derived metastases of a breast cancer cell line (M435) and when the latter was treated with a demethylation agent (5-azacytidine).	Azacitidine	155-168	BCL6 transcription repressor	Homo sapiens	0-5
18337495-4	2008	In this model, administration of the PPARdelta agonist GW0742 (1 or 10 mg/kg) substantially attenuated AngII-accelerated atherosclerosis without altering blood pressure and increased vascular expression of Bcl-6, RGS4, and RGS5, which was associated with suppression of inflammatory and atherogenic gene expression in the artery.	GW0742	55-61	BCL6 transcription repressor	Homo sapiens	206-211
19379553-4	2009	Meanwhile, PCR, cloning and direct DNA sequencing were used to identify mutations in the 5" regulatory region of bcl-6 in K562 cells before and after induction with TPA.	Tetradecanoylphorbol Acetate	165-168	BCL6 transcription repressor	Homo sapiens	113-118
18547747-3	2008	After 3-4-day DMSO treatment, zinc finger proteins 266 and 51 (BCL-6) were dramatically up-regulated, and additional gene expression changes, involving functional and signalling proteins as well as genes involved in RNA processing, apoptosis, and protein degradation, correlated with acquisition of the mature neutrophil phenotype.	Dimethyl Sulfoxide	14-18	BCL6 transcription repressor	Homo sapiens	63-68
18648506-8	2008	AFXzeta and alpha(198-505) lost the ability to transactivate BCL6 or suppress cyclin D2 gene expression.	afxzeta	0-7	BCL6 transcription repressor	Homo sapiens	61-65
17999414-12	2008	CONCLUSIONS: Bcl-6 expression was associated with a better prognosis in patients with PCNSL.	pcnsl	86-91	BCL6 transcription repressor	Homo sapiens	13-18
18048767-6	2008	Chromatin immunoprecipitation assays showed that GW0742 switched the association of BCL-6, a transcription repressor, from PPAR-delta to the vascular cell adhesion molecule (VCAM)-1 promoter.	GW0742	49-55	BCL6 transcription repressor	Homo sapiens	84-89
17689208-0	2007	Expression of STAT3 and Bcl-6 oncoprotein in sodium arsenite-treated SV-40 immortalized human uroepithelial cells.	sodium arsenite	45-60	BCL6 transcription repressor	Homo sapiens	24-29
17689208-6	2007	Our results showed that the expression of Bcl-6 increased dose-dependently in arsenite-treated urothelial cells.	arsenite	78-86	BCL6 transcription repressor	Homo sapiens	42-47
17689208-9	2007	Our data suggest that arsenic-mediated inactivation of the JAK-STAT signaling pathway might be caused by Bcl-6 interaction with JAK tyrosine kinase or STAT.	Arsenic	22-29	BCL6 transcription repressor	Homo sapiens	105-110
15377470-7	2004	Meta-analysis demonstrated that the preferentially altered sequence motifs of BCL6 in PMBL were TA (p=0.002) and AT (p=0.0008) dinucleotides and TAT trinucleotides (p=0.001).	Dinucleoside Phosphates	127-140	BCL6 transcription repressor	Homo sapiens	78-82
16815642-10	2007	BCL6 blockade can be achieved by different strategies which include siRNA, interference by specific peptides or regulation of BCL6 acetylation by pharmacological agents such as SAHA or niacinamide and would be applicable to most type of B-cell NHL.	Niacinamide	185-196	BCL6 transcription repressor	Homo sapiens	0-4
17134969-0	2006	Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.	Bortezomib	0-10	BCL6 transcription repressor	Homo sapiens	82-87
17134969-9	2006	Interesting, in IgVH mutated cells, Btz have statistically significant differences in their in vitro activity on B-CLL cells according to their BCL-6 mutational status.	Bortezomib	36-39	BCL6 transcription repressor	Homo sapiens	144-149
17134969-10	2006	CONCLUSIONS: Btz is a promising pharmacologic agent for the treatment of B-CLL, but its efficacy seems to be related to IgVH and BCL-6 mutational status, therefore, it could be interesting to further investigate the mechanisms involved in the different behavior of the cells in response to apoptosis induction by this drug.	Bortezomib	13-16	BCL6 transcription repressor	Homo sapiens	129-134
16618762-1	2006	SIRT1 and other NAD-dependent deacetylases have been implicated in control of cellular responses to stress and in tumorigenesis through deacetylation of important regulatory proteins, including p53 and the BCL6 oncoprotein.	NAD	16-19	BCL6 transcription repressor	Homo sapiens	206-210
16618762-4	2006	Treatment of BCL6-expressing Burkitt lymphoma cells with cambinol as a single agent induced apoptosis, which was accompanied by hyperacetylation of BCL6 and p53.	cambinol	57-65	BCL6 transcription repressor	Homo sapiens	13-17
16618762-4	2006	Treatment of BCL6-expressing Burkitt lymphoma cells with cambinol as a single agent induced apoptosis, which was accompanied by hyperacetylation of BCL6 and p53.	cambinol	57-65	BCL6 transcription repressor	Homo sapiens	148-152
16618762-5	2006	Because acetylation inactivates BCL6 and has the opposite effect on the function of p53 and other checkpoint pathways, the antitumor activity of cambinol in Burkitt lymphoma cells may be accomplished through a combined effect of BCL6 inactivation and checkpoint activation.	cambinol	145-153	BCL6 transcription repressor	Homo sapiens	32-36
16618762-5	2006	Because acetylation inactivates BCL6 and has the opposite effect on the function of p53 and other checkpoint pathways, the antitumor activity of cambinol in Burkitt lymphoma cells may be accomplished through a combined effect of BCL6 inactivation and checkpoint activation.	cambinol	145-153	BCL6 transcription repressor	Homo sapiens	229-233
16046671-0	2006	Genetic immunization: a new monoclonal antibody for the detection of BCL-6 protein in paraffin sections.	Paraffin	86-94	BCL6 transcription repressor	Homo sapiens	69-74
16046671-5	2006	Using GI191E/A8, the detection of BCL-6 protein was significantly increased, and its specificity was independent of formalin-fixation time.	Formaldehyde	116-124	BCL6 transcription repressor	Homo sapiens	34-39
16977965-12	2006	LMC showed: CD 20 (+), bcl-2 (-), CD 10 (+/-), and bcl-6 (+) in the follicle, and bcl-2 (+), CD10 (-/+) and bcl-6 (-) in the interfollicular area.	LMC	0-3	BCL6 transcription repressor	Homo sapiens	51-56
16977965-12	2006	LMC showed: CD 20 (+), bcl-2 (-), CD 10 (+/-), and bcl-6 (+) in the follicle, and bcl-2 (+), CD10 (-/+) and bcl-6 (-) in the interfollicular area.	LMC	0-3	BCL6 transcription repressor	Homo sapiens	108-113
15509806-3	2004	Inhibition of BCR-ABL by STI571 results in down-regulation of cyclin D2 expression, activation of FoxO3a activity, and up-regulation of BCL6 expression.	Imatinib Mesylate	25-31	BCL6 transcription repressor	Homo sapiens	136-140
15509806-8	2004	Furthermore, silencing of FoxO3a and BCL6 in BCR-ABL-expressing cells abolishes STI571-mediated effects on cyclin D2.	Imatinib Mesylate	80-86	BCL6 transcription repressor	Homo sapiens	37-41
17576390-4	2007	The BCL-6 gene (area B) was cloned and sequenced from peripheral blood mononuclear cells (PBMC) of 21 chronically HCV-infected patients with or without MC and B-NHL, and six healthy controls.	Methylcholanthrene	92-94	BCL6 transcription repressor	Homo sapiens	4-9
17392284-5	2007	A glutathione S-transferase pulldown assay revealed that HB-EGF-CTF interacted efficiently with zinc fingers 4-6 of Bcl6.	Glutathione	2-13	BCL6 transcription repressor	Homo sapiens	116-120
17088997-0	2006	Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling.	Resveratrol	0-11	BCL6 transcription repressor	Homo sapiens	135-139
17088997-4	2006	Resveratrol decreased the expression of BCL6 protein, concomitant with the increased expression of several BCL6 regulated gene products, including p27, p53 and CD69.	Resveratrol	0-11	BCL6 transcription repressor	Homo sapiens	40-44
17088997-4	2006	Resveratrol decreased the expression of BCL6 protein, concomitant with the increased expression of several BCL6 regulated gene products, including p27, p53 and CD69.	Resveratrol	0-11	BCL6 transcription repressor	Homo sapiens	107-111
17088997-6	2006	These results demonstrate for the first time that resveratrol inhibits a BCL6-linked pathway and suggest that loss of BCL6 expression may represent a key event underlying the anti-proliferative activities of resveratrol on LY8 cells.	Resveratrol	50-61	BCL6 transcription repressor	Homo sapiens	73-77
17088997-6	2006	These results demonstrate for the first time that resveratrol inhibits a BCL6-linked pathway and suggest that loss of BCL6 expression may represent a key event underlying the anti-proliferative activities of resveratrol on LY8 cells.	Resveratrol	208-219	BCL6 transcription repressor	Homo sapiens	73-77
17088997-6	2006	These results demonstrate for the first time that resveratrol inhibits a BCL6-linked pathway and suggest that loss of BCL6 expression may represent a key event underlying the anti-proliferative activities of resveratrol on LY8 cells.	Resveratrol	208-219	BCL6 transcription repressor	Homo sapiens	118-122
17088997-7	2006	The use of resveratrol to treat aggressive lymphomas with BCL6 and/or MYC translocations may prove useful as an effective therapy.	Resveratrol	11-22	BCL6 transcription repressor	Homo sapiens	58-62
15377470-7	2004	Meta-analysis demonstrated that the preferentially altered sequence motifs of BCL6 in PMBL were TA (p=0.002) and AT (p=0.0008) dinucleotides and TAT trinucleotides (p=0.001).	trinucleotides	149-163	BCL6 transcription repressor	Homo sapiens	78-82
15488654-0	2004	Possible interaction between activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen.	Tamoxifen	130-139	BCL6 transcription repressor	Homo sapiens	68-90
14750238-4	2004	Patients with high levels of bcl-6 expression had favorable overall survival (OS) (P = .003), disease-specific survival (DSS) (P = .033), and time to treatment failure (P = .003) compared with patients with low levels of bcl-6 expression.	dss	121-124	BCL6 transcription repressor	Homo sapiens	29-34
15488654-14	2004	We hypothesize that increased BCL-6 in breast cancer cells might block tamoxifen resistance by repressing AP-1, eventually resulting in apoptosis.	Tamoxifen	71-80	BCL6 transcription repressor	Homo sapiens	30-35
14655758-8	2003	Our results suggest translocation-mediated BCL6 oncogene activation as a so far unknown pathogenetically relevant mechanism in PCNSL.	pcnsl	127-132	BCL6 transcription repressor	Homo sapiens	43-47
14654791-3	2003	In this study, expression of BCL-6 was investigated by immunohistochemistry on paraffin-embedded specimens from 150 breast cancer patients and 10 specimens of normal breast tissue.	Paraffin	79-87	BCL6 transcription repressor	Homo sapiens	29-34
12907442-4	2003	B-cell lymphoma 6 (BCL6) mutations occurred in 25% P-PTLDs, 60.6% DLBCLs, and 75.0% BL/BLLs.	ptlds	53-58	BCL6 transcription repressor	Homo sapiens	0-17
12907442-4	2003	B-cell lymphoma 6 (BCL6) mutations occurred in 25% P-PTLDs, 60.6% DLBCLs, and 75.0% BL/BLLs.	ptlds	53-58	BCL6 transcription repressor	Homo sapiens	19-23
12811744-2	2003	We recently reported that BCL6 bodies associate with bromodeoxyuridine (BrdU)-substituted DNA, suggesting their implication in replication.	Bromodeoxyuridine	53-70	BCL6 transcription repressor	Homo sapiens	26-30
12881702-0	2003	BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells.	Reactive Oxygen Species	41-64	BCL6 transcription repressor	Homo sapiens	0-4
12881702-3	2003	In the present study, we established Daudi and Raji B-cell lymphoma cell lines that overexpress BCL6 or its mutant, BCL6-Ala333/343, in which serine residues required for degradation through the proteasome pathway in B-cell receptor-stimulated cells are mutated.	Serine	142-148	BCL6 transcription repressor	Homo sapiens	96-100
12881702-3	2003	In the present study, we established Daudi and Raji B-cell lymphoma cell lines that overexpress BCL6 or its mutant, BCL6-Ala333/343, in which serine residues required for degradation through the proteasome pathway in B-cell receptor-stimulated cells are mutated.	Serine	142-148	BCL6 transcription repressor	Homo sapiens	116-120
12881702-4	2003	BCL6 overexpression did not have any significant effect on cell proliferation, but significantly inhibited apoptosis caused by etoposide, which induced a proteasome-dependent degradation of BCL6.	Etoposide	127-136	BCL6 transcription repressor	Homo sapiens	0-4
12881702-4	2003	BCL6 overexpression did not have any significant effect on cell proliferation, but significantly inhibited apoptosis caused by etoposide, which induced a proteasome-dependent degradation of BCL6.	Etoposide	127-136	BCL6 transcription repressor	Homo sapiens	190-194
12881702-5	2003	BCL6-Ala333/343 was not degraded after etoposide treatment and strongly inhibited apoptosis.	Etoposide	39-48	BCL6 transcription repressor	Homo sapiens	0-4
12881702-8	2003	Furthermore, BCL6 overexpression was found to inhibit the increase in ROS levels and apoptosis in response to etoposide and other chemotherapeutic reagents.	Reactive Oxygen Species	70-73	BCL6 transcription repressor	Homo sapiens	13-17
12881702-8	2003	Furthermore, BCL6 overexpression was found to inhibit the increase in ROS levels and apoptosis in response to etoposide and other chemotherapeutic reagents.	Etoposide	110-119	BCL6 transcription repressor	Homo sapiens	13-17
12811744-3	2003	To examine this possibility, we examine here by electron and confocal microscopy the relation between BCL6 bodies and replication foci (RF) using incorporation of various halogenated nucleotides (BrdU, chlorodeoxyuridine, CldU, and iododeoxyuridine, IdU) or PCNA (proliferating cell nuclear antigen) staining.	5-chloro-2'-deoxyuridine	222-226	BCL6 transcription repressor	Homo sapiens	102-106
12811744-3	2003	To examine this possibility, we examine here by electron and confocal microscopy the relation between BCL6 bodies and replication foci (RF) using incorporation of various halogenated nucleotides (BrdU, chlorodeoxyuridine, CldU, and iododeoxyuridine, IdU) or PCNA (proliferating cell nuclear antigen) staining.	Idoxuridine	232-248	BCL6 transcription repressor	Homo sapiens	102-106
12811744-2	2003	We recently reported that BCL6 bodies associate with bromodeoxyuridine (BrdU)-substituted DNA, suggesting their implication in replication.	Bromodeoxyuridine	72-76	BCL6 transcription repressor	Homo sapiens	26-30
12811744-3	2003	To examine this possibility, we examine here by electron and confocal microscopy the relation between BCL6 bodies and replication foci (RF) using incorporation of various halogenated nucleotides (BrdU, chlorodeoxyuridine, CldU, and iododeoxyuridine, IdU) or PCNA (proliferating cell nuclear antigen) staining.	Idoxuridine	250-253	BCL6 transcription repressor	Homo sapiens	102-106
12171495-2	2002	DESIGN: We performed immunohistochemistry for detection of CD10 and Bcl-6 in paraffin-embedded tissue sections from 32 patients who had surgically resected primary intestinal lymphomas.	Paraffin	77-85	BCL6 transcription repressor	Homo sapiens	68-73
11865059-9	2002	A comparison of the PLZF, Bcl-6, and the FAZF (Fanconi anemia zinc finger)/ROG protein shows that variations in the BTB pocket result in differential affinity for corepressors, which predicts the potency of transcriptional repression.	btb	116-119	BCL6 transcription repressor	Homo sapiens	26-31
11972514-3	2002	We have developed a fluorescent in situ hybridization (FISH)-based technique for the retrospective analysis of the effect of BCL6 gene rearrangements on survival, using nuclei extracted from paraffin-embedded tissue.	Paraffin	191-199	BCL6 transcription repressor	Homo sapiens	125-129
11371365-4	2001	Inhibition of the pol zeta REV3 catalytic subunit by specific phosphorothioate-modified oligonucleotides impaired Ig and bcl-6 hypermutation and UV damage-induced DNA mutagenesis, without affecting cell cycle or viability.	Parathion	62-78	BCL6 transcription repressor	Homo sapiens	121-126
11341761-3	2001	To examine cell responses and target genes related to the BCL-6 signaling pathway, we established Ba/F3 pro-B cells carrying a human BCL-6 transgene that is inducible under control of the lactose operon.	Lactose	188-195	BCL6 transcription repressor	Homo sapiens	133-138
12940071-4	2001	RESULTS: Matrine could inhibit the proliferation of K562 cells with inhibition rate of 69% after 72 hours matrine induction; number of K562 cells increased significantly in G1 phase, and number of apoptotic cell was 68% at 5th day of matrine treated cells; the typical morphology of apoptotic cells of K562 cells was observed by electron microscopy; BCL-6 was increased and PCNA was decreased in K562 cells induced by matrine.	matrine	9-16	BCL6 transcription repressor	Homo sapiens	350-355
11371365-4	2001	Inhibition of the pol zeta REV3 catalytic subunit by specific phosphorothioate-modified oligonucleotides impaired Ig and bcl-6 hypermutation and UV damage-induced DNA mutagenesis, without affecting cell cycle or viability.	Oligonucleotides	88-104	BCL6 transcription repressor	Homo sapiens	121-126
11180008-10	2001	The ability of interferon-gamma to induce the transcription repressor BCL-6 may also contribute to the overall immunologic events in skin, including suppression of the intermediates in the synthetic pathway leading to expression of the T cell costimulatory ganglioside CDw60.	Gangliosides	257-268	BCL6 transcription repressor	Homo sapiens	70-75
11378576-0	2001	Paraffin immunoreactivity of CD10, CDw75, and Bcl-6 in follicle center cell lymphoma.	Paraffin	0-8	BCL6 transcription repressor	Homo sapiens	46-51
11046151-5	2000	Moreover, we show that a relatively low expression level of BCL6 reached after a brief induction in UTA-L cells is sufficient to observe its targeting to mid, late, and at least certain early replication foci visualized by a pulse-labeling with bromodeoxyuridine (BrdU).	Bromodeoxyuridine	245-262	BCL6 transcription repressor	Homo sapiens	60-64
11046151-5	2000	Moreover, we show that a relatively low expression level of BCL6 reached after a brief induction in UTA-L cells is sufficient to observe its targeting to mid, late, and at least certain early replication foci visualized by a pulse-labeling with bromodeoxyuridine (BrdU).	Bromodeoxyuridine	264-268	BCL6 transcription repressor	Homo sapiens	60-64
11027625-0	2000	Apoptosis and restriction of G(1)/S cell cycle by fenretinide in Burkitt"s lymphoma mutu I cell line accessed with bcl-6 down-regulation.	Fenretinide	50-61	BCL6 transcription repressor	Homo sapiens	115-120
10396291-8	1999	We analyzed Bcl-6 staining of formalin-fixed paraffin-embedded tissue from 72 indolent lymphomas including 31 grade I and II follicle center lymphomas (FCL).	Formaldehyde	30-38	BCL6 transcription repressor	Homo sapiens	12-17
10978285-6	2000	Interestingly, the Ttk69 BTB can be substituted by the BTB of the human Bcl-6 protein, suggesting that BTB function has been conserved between Drosophila and humans.	btb	55-58	BCL6 transcription repressor	Homo sapiens	72-77
10978285-6	2000	Interestingly, the Ttk69 BTB can be substituted by the BTB of the human Bcl-6 protein, suggesting that BTB function has been conserved between Drosophila and humans.	btb	55-58	BCL6 transcription repressor	Homo sapiens	72-77
10878357-4	2000	In this paper we showed that the same stimuli induce somatic hypermutation of bcl-6 in CL-01 and normal IgM+ IgD+ B cells.	cl-01	87-92	BCL6 transcription repressor	Homo sapiens	78-83
10843287-0	2000	CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas.	Paraffin	29-37	BCL6 transcription repressor	Homo sapiens	9-14
10843287-1	2000	In this study the authors explored the value of immunostaining for follicular center B-cell markers, BCL-6 and CD10, in paraffin sections as a tool for the differential diagnosis of B-cell lymphomas.	Paraffin	120-128	BCL6 transcription repressor	Homo sapiens	101-106
10490843-5	1999	To directly address this issue, we used a tetracycline-regulated system in human U2OS osteosarcoma cells and thus found that BCL6 mediates growth suppression associated with impaired S phase progression and apoptosis.	Tetracycline	42-54	BCL6 transcription repressor	Homo sapiens	125-129
10396291-8	1999	We analyzed Bcl-6 staining of formalin-fixed paraffin-embedded tissue from 72 indolent lymphomas including 31 grade I and II follicle center lymphomas (FCL).	Paraffin	45-53	BCL6 transcription repressor	Homo sapiens	12-17
9927205-1	1999	The BCL-6 proto-oncogene encodes a 92- to 98-kDa transcriptional repressor containing the BTB/POZ domain at its N-terminal region and the zinc finger domain at its C-terminal region, respectively.	btb	90-93	BCL6 transcription repressor	Homo sapiens	4-9
10208461-6	1999	MATERIALS AND METHODS: Formalin-fixed paraffin sections were used for immunostaining of Bcl-6.	Formaldehyde	23-31	BCL6 transcription repressor	Homo sapiens	88-93
10208461-6	1999	MATERIALS AND METHODS: Formalin-fixed paraffin sections were used for immunostaining of Bcl-6.	Paraffin	38-46	BCL6 transcription repressor	Homo sapiens	88-93
8623923-0	1996	Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region.	Formaldehyde	90-96	BCL6 transcription repressor	Homo sapiens	128-133
9632807-7	1998	The 17-amino-acid sequence in the middle portion was completely conserved between BAZF and Bcl6, and the conserved region was critical for the repressor activity.	17-amino-acid	4-17	BCL6 transcription repressor	Homo sapiens	91-95
9188861-0	1997	BCL-6 is phosphorylated at multiple sites in its serine- and proline-clustered region by mitogen-activated protein kinase (MAPK) in vivo.	Serine	49-55	BCL6 transcription repressor	Homo sapiens	0-5
9188861-0	1997	BCL-6 is phosphorylated at multiple sites in its serine- and proline-clustered region by mitogen-activated protein kinase (MAPK) in vivo.	Proline	61-68	BCL6 transcription repressor	Homo sapiens	0-5
9188861-6	1997	BCL-6 phosphorylation significantly increased in Ramos cells following stimulation with 12-o-tetradecanoylphorbol-13-acetate (TPA) or BCL-6- and erk1-transfected COS-7 cells stimulated with epidermal growth factor (EGF), and the increase of phosphorylation was inhibited by MEK1 inhibitor, PD98059.	Tetradecanoylphorbol Acetate	88-124	BCL6 transcription repressor	Homo sapiens	0-5
9188861-6	1997	BCL-6 phosphorylation significantly increased in Ramos cells following stimulation with 12-o-tetradecanoylphorbol-13-acetate (TPA) or BCL-6- and erk1-transfected COS-7 cells stimulated with epidermal growth factor (EGF), and the increase of phosphorylation was inhibited by MEK1 inhibitor, PD98059.	Tetradecanoylphorbol Acetate	126-129	BCL6 transcription repressor	Homo sapiens	0-5
9188861-6	1997	BCL-6 phosphorylation significantly increased in Ramos cells following stimulation with 12-o-tetradecanoylphorbol-13-acetate (TPA) or BCL-6- and erk1-transfected COS-7 cells stimulated with epidermal growth factor (EGF), and the increase of phosphorylation was inhibited by MEK1 inhibitor, PD98059.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	290-297	BCL6 transcription repressor	Homo sapiens	0-5
9180294-3	1997	Although the expression of BCL-6 transcripts was very low or undetectable in untreated HL-60 or U-937 cells, treatment of these cells with TPA to induce monocytic differentiation resulted in an apparent increase of BCL-6 mRNA, suggesting that BCL-6 gene expression is not limited to B cells and it is closely associated with monocytic lineage differentiation.	Tetradecanoylphorbol Acetate	139-142	BCL6 transcription repressor	Homo sapiens	27-32
9180294-3	1997	Although the expression of BCL-6 transcripts was very low or undetectable in untreated HL-60 or U-937 cells, treatment of these cells with TPA to induce monocytic differentiation resulted in an apparent increase of BCL-6 mRNA, suggesting that BCL-6 gene expression is not limited to B cells and it is closely associated with monocytic lineage differentiation.	Tetradecanoylphorbol Acetate	139-142	BCL6 transcription repressor	Homo sapiens	215-220
9180294-3	1997	Although the expression of BCL-6 transcripts was very low or undetectable in untreated HL-60 or U-937 cells, treatment of these cells with TPA to induce monocytic differentiation resulted in an apparent increase of BCL-6 mRNA, suggesting that BCL-6 gene expression is not limited to B cells and it is closely associated with monocytic lineage differentiation.	Tetradecanoylphorbol Acetate	139-142	BCL6 transcription repressor	Homo sapiens	215-220
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Tetradecanoylphorbol Acetate	25-28	BCL6 transcription repressor	Homo sapiens	4-9
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Tetradecanoylphorbol Acetate	25-28	BCL6 transcription repressor	Homo sapiens	134-139
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Cycloheximide	89-102	BCL6 transcription repressor	Homo sapiens	4-9
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Cycloheximide	104-107	BCL6 transcription repressor	Homo sapiens	4-9
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Tetradecanoylphorbol Acetate	175-178	BCL6 transcription repressor	Homo sapiens	4-9
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Tetradecanoylphorbol Acetate	175-178	BCL6 transcription repressor	Homo sapiens	134-139
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Dactinomycin	238-251	BCL6 transcription repressor	Homo sapiens	4-9
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Dactinomycin	238-251	BCL6 transcription repressor	Homo sapiens	134-139
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Dactinomycin	253-256	BCL6 transcription repressor	Homo sapiens	4-9
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Dactinomycin	253-256	BCL6 transcription repressor	Homo sapiens	134-139
9180294-5	1997	Furthermore, the nuclear run-on assay revealed that the BCL-6 transcription signals were enhanced by TPA treatment.	Tetradecanoylphorbol Acetate	101-104	BCL6 transcription repressor	Homo sapiens	56-61
9180294-6	1997	These results suggest that the increase of BCL-6 mRNA in U-937 cells stimulated with TPA to induce monocytic lineage differentiation is mediated by both transcriptional and post-transcriptional regulation.	Tetradecanoylphorbol Acetate	85-88	BCL6 transcription repressor	Homo sapiens	43-48
9096701-2	1997	Therefore we studied the expression pattern of LAZ3/BCL6 by in situ hybridization with synthetic oligonucleotide probes in frozen tissue sections from five reactive lymph nodes and 38 B cell and non-B NHL.	Oligonucleotides	97-112	BCL6 transcription repressor	Homo sapiens	47-51
9209651-4	1997	PG-B6p (p = paraffin) reacted with an epitope of bcl-6 partially resistant to fixatives and detectable on microwave-heated paraffin sections.	Paraffin	12-20	BCL6 transcription repressor	Homo sapiens	49-54
9209651-4	1997	PG-B6p (p = paraffin) reacted with an epitope of bcl-6 partially resistant to fixatives and detectable on microwave-heated paraffin sections.	Paraffin	123-131	BCL6 transcription repressor	Homo sapiens	49-54
8623923-5	1996	PG-B6p (p is for paraffin) recognized a fixative-resistant epitope of BCL-6 that was detectable on paraffin sections after microwave heating in 1 mmol/L EDTA buffer.	Paraffin	17-25	BCL6 transcription repressor	Homo sapiens	70-75
8623923-5	1996	PG-B6p (p is for paraffin) recognized a fixative-resistant epitope of BCL-6 that was detectable on paraffin sections after microwave heating in 1 mmol/L EDTA buffer.	Paraffin	99-107	BCL6 transcription repressor	Homo sapiens	70-75
8623923-5	1996	PG-B6p (p is for paraffin) recognized a fixative-resistant epitope of BCL-6 that was detectable on paraffin sections after microwave heating in 1 mmol/L EDTA buffer.	Edetic Acid	153-157	BCL6 transcription repressor	Homo sapiens	70-75
8623923-10	1996	Labeling of paraffin sections with PG-B6p proved useful for differentiating proliferation centers in B-CLL (BCl-2+/BCL-6-) from trapped germinal centers in mantle cell lymphomas (BCL-2-/BCL-6+) and for identifying neoplastic cells in cases of nodular, lymphocyte-predominance Hodgkin"s disease.	Paraffin	12-20	BCL6 transcription repressor	Homo sapiens	115-120
8623923-10	1996	Labeling of paraffin sections with PG-B6p proved useful for differentiating proliferation centers in B-CLL (BCl-2+/BCL-6-) from trapped germinal centers in mantle cell lymphomas (BCL-2-/BCL-6+) and for identifying neoplastic cells in cases of nodular, lymphocyte-predominance Hodgkin"s disease.	Paraffin	12-20	BCL6 transcription repressor	Homo sapiens	186-191
7945383-4	1994	In a gel mobility shift assay, the probe containing the 14-nucleotide recognition sequence formed a complex with the fusion protein and nuclear proteins from Burkitt"s cell lines overexpressing the BCL6 transcripts.	14-nucleotide	56-69	BCL6 transcription repressor	Homo sapiens	198-202
9019154-8	1995	Indeed, on the LAZ3/BCL6 cognate sequence, deletion of the BTB/POZ domain diminishes the repressive function.	btb	59-62	BCL6 transcription repressor	Homo sapiens	15-19
9019154-8	1995	Indeed, on the LAZ3/BCL6 cognate sequence, deletion of the BTB/POZ domain diminishes the repressive function.	btb	59-62	BCL6 transcription repressor	Homo sapiens	20-24
7639334-4	1995	By immunocytochemical analysis, BCL-6 localizes in the nucleus where PG-B6 staining gives a microgranular/diffuse pattern with exclusion of the nucleoli.	pg-b6	69-74	BCL6 transcription repressor	Homo sapiens	32-37
35503721-8	2022	Accordingly, targeted inhibition of BCL6 remarkably enhanced etoposide-triggered DNA damage and apoptosis both in vitro and in vivo.	Etoposide	61-70	BCL6 transcription repressor	Homo sapiens	36-40
33807449-5	2021	Together, 66.7% of DH/TH-HGBL patients were BCL6 rearrangement positive.	Thorium	22-24	BCL6 transcription repressor	Homo sapiens	44-48
34504602-0	2021	Upregulation of miR-144-3p expression attenuates glioma cell viability and invasion by targeting BCL6.	mir-144-3p	16-26	BCL6 transcription repressor	Homo sapiens	97-101
34504602-7	2021	Luciferase reporter assay was used to assess the association between miR-144-3p and BCL6 and a tumor xenograft model was established for assess tumor growth.	mir-144-3p	69-79	BCL6 transcription repressor	Homo sapiens	84-88
34126157-7	2021	In addition, the current study demonstrated that Bcl6 upregulation was responsible for repression of BAG5 transactivation via recruitment on the BAG5 promoter in cisplatin-resistant ovarian cancer.	Cisplatin	162-171	BCL6 transcription repressor	Homo sapiens	49-53
34126157-9	2021	Collectively, the current study identified the implication of Bcl6/BAG5/Rictor-mTORC2 signaling pathway in metabolic reprograming and maintenance of CSC-like features in cisplatin-resistant ovarian cancer cells.	Cisplatin	170-179	BCL6 transcription repressor	Homo sapiens	62-66
33768318-3	2021	In this study, we aim to validate the diagnostic performance of multiplex BCL2/BCL6 FISH approach in formalin-fixed paraffin-embedded FLs and DBCLs and cytological samples of DLBCL comparing to the classic set of single break-apart probes.	Formaldehyde	101-109	BCL6 transcription repressor	Homo sapiens	79-83
33768318-3	2021	In this study, we aim to validate the diagnostic performance of multiplex BCL2/BCL6 FISH approach in formalin-fixed paraffin-embedded FLs and DBCLs and cytological samples of DLBCL comparing to the classic set of single break-apart probes.	Paraffin	116-124	BCL6 transcription repressor	Homo sapiens	79-83
34727403-2	2022	DHL/THL is called as "high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements" in the World Health Organization 2017 Classification of Tumors of Hematopoietic and Lymphoid Tissues.	Orlistat	4-7	BCL6 transcription repressor	Homo sapiens	74-78
34614509-0	2021	Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia.	gilteritinib	0-12	BCL6 transcription repressor	Homo sapiens	64-68
34614509-5	2021	Using a transcription factor screen, we identified the transcriptional corepressor BCL6, as a regulator of S100A9 expression, and found that gilteritinib decreased BCL6 binding to the S100A9 promoter, thereby increasing S100A9 expression.	gilteritinib	141-153	BCL6 transcription repressor	Homo sapiens	83-87
34614509-5	2021	Using a transcription factor screen, we identified the transcriptional corepressor BCL6, as a regulator of S100A9 expression, and found that gilteritinib decreased BCL6 binding to the S100A9 promoter, thereby increasing S100A9 expression.	gilteritinib	141-153	BCL6 transcription repressor	Homo sapiens	164-168
34614509-6	2021	Furthermore, pharmacological inhibition of BCL6 accelerated the growth rate of gilteritinib-resistant FLT3-ITD+ AML cells, suggesting that S100A9 is a functional target of BCL6.	gilteritinib	79-91	BCL6 transcription repressor	Homo sapiens	43-47
34614509-6	2021	Furthermore, pharmacological inhibition of BCL6 accelerated the growth rate of gilteritinib-resistant FLT3-ITD+ AML cells, suggesting that S100A9 is a functional target of BCL6.	gilteritinib	79-91	BCL6 transcription repressor	Homo sapiens	172-176
34846884-0	2021	Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated Pocket.	Water	10-15	BCL6 transcription repressor	Homo sapiens	28-32
34846884-1	2021	We describe the optimization of modestly active starting points to potent inhibitors of BCL6 by growing into a subpocket, which was occupied by a network of five stably bound water molecules.	Water	175-180	BCL6 transcription repressor	Homo sapiens	88-92
34464595-4	2021	BCL6 impinged on Tfh calcium signaling and also controlled Tfh entanglement with and CD40L delivery to B cells.	Calcium	21-28	BCL6 transcription repressor	Homo sapiens	0-4
34334687-6	2021	Compared with FL3A, FL3U exhibited higher MUM1 and Ki67 expression, less BCL2 breaks and more BCL6 rearrangements, together with a higher number of cases without any BCL2, BCL6 or MYC rearrangement.	fl3u	20-24	BCL6 transcription repressor	Homo sapiens	94-98
34334687-6	2021	Compared with FL3A, FL3U exhibited higher MUM1 and Ki67 expression, less BCL2 breaks and more BCL6 rearrangements, together with a higher number of cases without any BCL2, BCL6 or MYC rearrangement.	fl3u	20-24	BCL6 transcription repressor	Homo sapiens	172-176
35481444-5	2022	All patients required to have the diagnosis of DHL/THL by FISH for rearrangements of MYC, BCL2, and BCL6.	Orlistat	51-54	BCL6 transcription repressor	Homo sapiens	100-104
35499081-6	2022	The subsequent loss of BDH2 drove labile iron to accumulate in the cytoplasm and promoted TET enzyme activity, BCL6 gene demethylation, and Tfh cell differentiation.	Iron	41-45	BCL6 transcription repressor	Homo sapiens	111-115
35100079-9	2022	However, the inhibitory effect of si-BCL6 was abrogated by miR-30b-5p inhibitor.	mir-30b	59-66	BCL6 transcription repressor	Homo sapiens	37-41
33036022-9	2021	In accordance with the effects of GCK knockdown, the GCK inhibitor TL4-12 dose-dependently downregulated IKZF1 and BCL-6 and led to MM cell proliferation inhibition accompanied by induction of apoptosis.	TL4-12	67-73	BCL6 transcription repressor	Homo sapiens	115-120
35039330-6	2022	Consistently, BCL6 expression was sustained following T cell activation of GPA naive CD4 T cells and in vitro TFH differentiation of these cells resulted in significant increases in the production TFH-related cytokines IL-21 and IL-6.	tfh	110-113	BCL6 transcription repressor	Homo sapiens	14-18
35039330-6	2022	Consistently, BCL6 expression was sustained following T cell activation of GPA naive CD4 T cells and in vitro TFH differentiation of these cells resulted in significant increases in the production TFH-related cytokines IL-21 and IL-6.	tfh	197-200	BCL6 transcription repressor	Homo sapiens	14-18
35123611-0	2022	(The Relationship between MicroRNA Expression Profiling in Imatinib-Resistant Cell Line K562/G and Potential Mechanism through FOXO3/Bcl-6 Signaling Pathway).	Imatinib Mesylate	59-67	BCL6 transcription repressor	Homo sapiens	133-138
35123611-11	2022	CONCLUSION: The FOXO3/Bcl-6 signaling pathway contributes to imatinib resistance in K562/G cell line, and the miRNA expression profiles showed significant differences between K562/G and K562 cells.	Imatinib Mesylate	61-69	BCL6 transcription repressor	Homo sapiens	22-27
34027881-8	2021	Furthermore, it was found that a significantly higher percentage of TFH cells and levels of IL-21 and Bcl-6 in RMPP children, compared with GMPP children (all p <0.05).	rmpp	111-115	BCL6 transcription repressor	Homo sapiens	102-107
33147467-4	2020	IL-4 signaling alters the metabolomic profile in activated B cells and induces accumulation of the TCA cycle intermediate alpha-ketoglutarate (alphaKG), which is required for activation of the Bcl6 gene locus.	Trichloroacetic Acid	99-102	BCL6 transcription repressor	Homo sapiens	193-197
33728745-5	2021	Here, we investigated the effects of o,p"-DDT, p,p"-DDT, and endosulfan and of hormones estradiol, testosterone, and progesterone on the expression of estrogen, progesterone, and androgen receptors (ER, PR, and AR) and of their target genes (KLF4, VEGFA, CCND1, PRLR, CDKN1A, and BCL6) in MCF-7 and MDA-MB-231 cells.	Progesterone	117-129	BCL6 transcription repressor	Homo sapiens	280-284
33551436-0	2021	DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.	da-epoch-r	0-10	BCL6 transcription repressor	Homo sapiens	75-79
33694215-9	2021	UBLRu-87 and UBBB-55 induced the expression of CJUN, CFOS and CASP-9 but not BCL-6.	ubbb	13-17	BCL6 transcription repressor	Homo sapiens	77-82
33629212-0	2021	Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.	ibrutinib	55-64	BCL6 transcription repressor	Homo sapiens	15-19
33629212-10	2021	In addition, another expression profile from GEO database showed that BCL6 was significantly high expression in no responsive patients after Ibrutinib treatment, and the receiver operating characteristic (ROC) curve which was used to evaluate the relationship between BCL6 expression and its effect was 0.67.	ibrutinib	141-150	BCL6 transcription repressor	Homo sapiens	70-74
33629212-11	2021	MTT assay showed that treatment with FX1 (a BCL6 inhibitor) can enhance the sensitivity of Ibrutinib in C481S BTK HBL-1 cells.	monooxyethylene trimethylolpropane tristearate	0-3	BCL6 transcription repressor	Homo sapiens	44-48
33629212-11	2021	MTT assay showed that treatment with FX1 (a BCL6 inhibitor) can enhance the sensitivity of Ibrutinib in C481S BTK HBL-1 cells.	ibrutinib	91-100	BCL6 transcription repressor	Homo sapiens	44-48
33629212-12	2021	The results suggested that BCL6 and miR-30 family maybe associate with Ibrutinib resistance in ABC-DLBCL.	ibrutinib	71-80	BCL6 transcription repressor	Homo sapiens	27-31
33393503-0	2021	BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.	bet inhibitors	66-80	BCL6 transcription repressor	Homo sapiens	0-4
33393503-6	2021	Importantly, pharmacological inhibition of either BCL6 or mTOR improved the tumor response and enhanced the sensitivity of KRAS-mutant NSCLC to BETi in both in vitro and in vivo settings.	beti	144-148	BCL6 transcription repressor	Homo sapiens	50-54
33208943-4	2020	BI-3802 is a small molecule that binds to the Broad-complex, Tramtrack and Bric-a-brac (BTB) domain of the oncogenic transcription factor B cell lymphoma 6 (BCL6) and leads to the proteasomal degradation of BCL66.	BI-3802	0-7	BCL6 transcription repressor	Homo sapiens	138-155
33208943-4	2020	BI-3802 is a small molecule that binds to the Broad-complex, Tramtrack and Bric-a-brac (BTB) domain of the oncogenic transcription factor B cell lymphoma 6 (BCL6) and leads to the proteasomal degradation of BCL66.	BI-3802	0-7	BCL6 transcription repressor	Homo sapiens	157-161
33208943-7	2020	Our findings demonstrate that a small molecule such as BI-3802 can induce polymerization coupled to highly specific protein degradation, which in the case of BCL6 leads to increased pharmacological activity compared to the effects induced by other BCL6 inhibitors.	BI-3802	55-62	BCL6 transcription repressor	Homo sapiens	158-162
33208943-7	2020	Our findings demonstrate that a small molecule such as BI-3802 can induce polymerization coupled to highly specific protein degradation, which in the case of BCL6 leads to increased pharmacological activity compared to the effects induced by other BCL6 inhibitors.	BI-3802	55-62	BCL6 transcription repressor	Homo sapiens	248-252
33147467-4	2020	IL-4 signaling alters the metabolomic profile in activated B cells and induces accumulation of the TCA cycle intermediate alpha-ketoglutarate (alphaKG), which is required for activation of the Bcl6 gene locus.	Ketoglutaric Acids	122-141	BCL6 transcription repressor	Homo sapiens	193-197
32180900-5	2020	Here, we have utilized tetracycline-inducible CRISPR/Cas9 mutagenesis to study the consequences of BCL6 deletion in established DLBCL models in culture and in vivo.	Tetracycline	23-35	BCL6 transcription repressor	Homo sapiens	99-103
32851455-0	2020	A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH/CCND1 translocation.	Methotrexate	2-14	BCL6 transcription repressor	Homo sapiens	75-79
31898356-8	2020	The relative mRNA abundance of BAK, BAX, CASP3, CASP8, and TP53 and protein abundance of Bak, cleaved caspase-3, caspase-8, and P53 was activated by U73122 or inhibited by m-3M3FBS, while the relative mRNA and protein level of BCL6 showed the opposite trend.	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	149-155	BCL6 transcription repressor	Homo sapiens	227-231
32061875-6	2020	Under the control of certain cytokines and B-cell lymphoma 6 transcription factor (Bcl-6); the major transcription factor of TFH cells; TFH can expand to the other distinct CD4 + T helper cells (TH1, TH2 and TH17) which exert different role in the development of CRC.	meso-tetrakis(heptafluoropropyl)porphyrin	125-128	BCL6 transcription repressor	Homo sapiens	83-88
32061875-6	2020	Under the control of certain cytokines and B-cell lymphoma 6 transcription factor (Bcl-6); the major transcription factor of TFH cells; TFH can expand to the other distinct CD4 + T helper cells (TH1, TH2 and TH17) which exert different role in the development of CRC.	meso-tetrakis(heptafluoropropyl)porphyrin	136-139	BCL6 transcription repressor	Homo sapiens	83-88
32320427-5	2020	Further, treatment with the standard therapies for glioblastoma-ionizing radiation and temozolomide-both induced BCL6 expression in vitro, and an in vivo orthotopic animal model of glioblastoma.	Temozolomide	87-99	BCL6 transcription repressor	Homo sapiens	113-117
32551010-0	2020	Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.	Tyrosine	59-67	BCL6 transcription repressor	Homo sapiens	29-33
32551010-3	2020	Here, we report the development of an irreversible BCL6 inhibitor TMX-2164 that uses a sulfonyl fluoride to covalently react with the hydroxyl group of Tyrosine 58 located in the lateral groove.	sulfuryl fluoride	87-104	BCL6 transcription repressor	Homo sapiens	51-55
32551010-3	2020	Here, we report the development of an irreversible BCL6 inhibitor TMX-2164 that uses a sulfonyl fluoride to covalently react with the hydroxyl group of Tyrosine 58 located in the lateral groove.	Tyrosine	152-160	BCL6 transcription repressor	Homo sapiens	51-55
32551010-5	2020	TMX-2164 therefore represents an example of a tyrosine-directed covalent inhibitor of BCL6 which demonstrates advantages relative to reversible targeting.	tmx-2164	0-8	BCL6 transcription repressor	Homo sapiens	86-90
32551010-5	2020	TMX-2164 therefore represents an example of a tyrosine-directed covalent inhibitor of BCL6 which demonstrates advantages relative to reversible targeting.	Tyrosine	46-54	BCL6 transcription repressor	Homo sapiens	86-90
32311849-7	2020	A complex karyotype with aberrations related to regions in MYC and BCL2/BCL6 was significantly associated with D/THL.	Deuterium	111-112	BCL6 transcription repressor	Homo sapiens	72-76
32311849-7	2020	A complex karyotype with aberrations related to regions in MYC and BCL2/BCL6 was significantly associated with D/THL.	Orlistat	113-116	BCL6 transcription repressor	Homo sapiens	72-76
32780847-9	2020	Importantly, BCL6 translocations identified non-GCB lymphomas with favorable BN2/C1-like survival independent of IPI and concurrent DPE status.	diprotin A	113-116	BCL6 transcription repressor	Homo sapiens	13-17
32033748-0	2020	Ubiquitin-specific protease 14 regulates ovarian cancer cisplatin-resistance by stabilizing BCL6 oncoprotein.	Cisplatin	56-65	BCL6 transcription repressor	Homo sapiens	92-96
32033748-5	2020	Genetic or pharmacological inhibition of USP14 is able to reverse cisplatin-resistance of ovarian cancer cells, which was accompanied by decreased protein expression of BCL6.	Cisplatin	66-75	BCL6 transcription repressor	Homo sapiens	169-173
32033748-6	2020	Besides, BCL6 protein level was also increased in cisplatin-resistant ovarian cancer cells and silencing of BCL6 in these cells restored their sensitivity to cisplatin.	Cisplatin	50-59	BCL6 transcription repressor	Homo sapiens	9-13
32033748-6	2020	Besides, BCL6 protein level was also increased in cisplatin-resistant ovarian cancer cells and silencing of BCL6 in these cells restored their sensitivity to cisplatin.	Cisplatin	158-167	BCL6 transcription repressor	Homo sapiens	9-13
32033748-6	2020	Besides, BCL6 protein level was also increased in cisplatin-resistant ovarian cancer cells and silencing of BCL6 in these cells restored their sensitivity to cisplatin.	Cisplatin	158-167	BCL6 transcription repressor	Homo sapiens	108-112
31895575-2	2020	In this article, a series of N-phenyl-4-pyrimidinamine derivatives were designed and synthesized as potent BCL6 inhibitors by optimizing hit compound N4-(3-chloro-4-methoxyphenyl)-N2-isobutyl-5-fluoro-2,4-pyrimidinediamine on the basis of the structure-activity relationship.	4-amino-2-methoxypyrimidine	29-54	BCL6 transcription repressor	Homo sapiens	107-111
31831210-5	2020	RESULTS: In the absence of donor skin sensitization, long-term heart allograft survival was achieved in the Mtorfl/flCd4-Cre recipients, which was associated with significantly decreased frequencies of CD62L-CD44+ effector T cells and BCL-6+CXCR5+ T follicular helper (Tfh) cells in the periphery.	1,5-dihydro-3-(3-sulfopropyl)lumiflavin	115-119	BCL6 transcription repressor	Homo sapiens	235-240
31895575-2	2020	In this article, a series of N-phenyl-4-pyrimidinamine derivatives were designed and synthesized as potent BCL6 inhibitors by optimizing hit compound N4-(3-chloro-4-methoxyphenyl)-N2-isobutyl-5-fluoro-2,4-pyrimidinediamine on the basis of the structure-activity relationship.	2,4-diamino-5-methylpyrimidine	150-222	BCL6 transcription repressor	Homo sapiens	107-111
31288832-1	2019	Double/triple-hit lymphomas (DHL/THL) account for 5-10% of diffuse large B cell lymphoma (DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC overexpression.	Orlistat	33-36	BCL6 transcription repressor	Homo sapiens	139-143
32378621-9	2020	On the other hand, in comparison between cancer sphere and sphere with VPA treatment, we detected 29 probe of methylation status change, and VPA reduced the expressions of Bcl-6 in sphere.	Valproic Acid	141-144	BCL6 transcription repressor	Homo sapiens	172-177
31375635-4	2019	In a temperature-dependent manner, BCL6 suppresses apoptosis, fatty acid storage, and coupled respiration to maintain thermogenic fitness during dormancy.	Fatty Acids	62-72	BCL6 transcription repressor	Homo sapiens	35-39
31308445-11	2019	For the first time, we report the ability of NAM to augment PARP1 activation, induced by RSV, and its associated anti-inflammatory effects mediated through the induction of BCL6 with the concomitant down regulation of COX-2.	Niacinamide	45-48	BCL6 transcription repressor	Homo sapiens	173-177
31903146-9	2020	At molecular level, BCL6 inhibited forkhead box O3 (FOXO3) transcription, subsequent translation and upregulation of phosphorylated/inactive FOXO3 through phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) and/or epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase 1/2 (MAP2K1/2) signaling pathway(s).	cholecystokinin C-terminal flanking peptide	192-198	BCL6 transcription repressor	Homo sapiens	20-24
31903146-9	2020	At molecular level, BCL6 inhibited forkhead box O3 (FOXO3) transcription, subsequent translation and upregulation of phosphorylated/inactive FOXO3 through phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) and/or epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase 1/2 (MAP2K1/2) signaling pathway(s).	glycyl-threonine	199-208	BCL6 transcription repressor	Homo sapiens	20-24
31712669-3	2019	In this study romidepsin, a potent histone deacetylase inhibitor (HDACi), induced apoptosis and cell cycle arrest in Burkitt and diffuse large B-cell lymphoma cell lines, which are model cells for studying the mechanism of action of BCL6.	romidepsin	14-24	BCL6 transcription repressor	Homo sapiens	233-237
31712669-4	2019	Romidepsin caused BCL6 acetylation at early timepoints inhibiting its function, while at later timepoints BCL6 expression was reduced and target gene expression increased due to chromatin modification.	romidepsin	0-10	BCL6 transcription repressor	Homo sapiens	18-22
31419226-0	2019	DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.	3-deazaneplanocin	0-5	BCL6 transcription repressor	Homo sapiens	119-123
31419226-6	2019	We show that DZNep inhibits proliferation and induces apoptosis of these cell lines independent of the type of lymphoma, the EZH2 mutation status and the MYC, BCL2 and BCL6 rearrangement status.	3-deazaneplanocin	13-18	BCL6 transcription repressor	Homo sapiens	168-172
31336593-6	2019	We found a correlation between BCL6 overexpression and resistance to etoposide.	Etoposide	69-78	BCL6 transcription repressor	Homo sapiens	31-35
30907193-7	2019	Production of IL-17 and IL-21 and the expression of RORgammat and BCL6 was diminished in patients treated with combined sitagliptin and VitD3, whereas the production of IL-37 and FOXP3 expression were increased in the patients treated with sitagliptin or sitagliptin plus VitD3.	Sitagliptin Phosphate	120-131	BCL6 transcription repressor	Homo sapiens	66-70
30777872-3	2019	We find that the highly conserved BTB corepressor binding site of BCL6 mediates stress adaptation across vertebrates.	btb	34-37	BCL6 transcription repressor	Homo sapiens	66-70
30210134-0	2019	Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements.	gemcitabine	0-11	BCL6 transcription repressor	Homo sapiens	138-142
30998141-2	2019	METHODS: Western blot was used to detect the expression of BCL6 in K562/G01 cells before and after treatment with protease inhibitor MG-132.The RT-PCR and Western blot respectively were used to detect the mRNA and protein expression levels of BCL6 and USP2 in K562/G01 cells treated with or without ML364 (a ubiquitin-specific protease USP2 inhibitor).	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	133-139	BCL6 transcription repressor	Homo sapiens	59-63
30998141-2	2019	METHODS: Western blot was used to detect the expression of BCL6 in K562/G01 cells before and after treatment with protease inhibitor MG-132.The RT-PCR and Western blot respectively were used to detect the mRNA and protein expression levels of BCL6 and USP2 in K562/G01 cells treated with or without ML364 (a ubiquitin-specific protease USP2 inhibitor).	ML364	299-304	BCL6 transcription repressor	Homo sapiens	59-63
30998141-4	2019	RESULTS: After treatment with protease inhibitor MG132, the BCL6 protein level of K562/G01 significantly increased (P&lt;0.05).	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	49-54	BCL6 transcription repressor	Homo sapiens	60-64
30998141-6	2019	After treatment of K562/G01 with USP2 protease inhibitor ML364, the expression levels of USP2 and BCL6 proteins were down-regulated simultaneously (P &lt;0.05) .	ML364	57-62	BCL6 transcription repressor	Homo sapiens	98-102
30907193-8	2019	Conclusion: These data demonstrate that sitagliptin in combination with VitD3 may accelerate the process of T2DM treatment by exerting synergic anti-inflammatory effects on immune system through upregulation of FOXP3 and IL-37, and downregulation of RORgammat and BCL6 as well as IFN-gamma, IL-17 and IL-21 production.	Sitagliptin Phosphate	40-51	BCL6 transcription repressor	Homo sapiens	264-268
30832685-0	2019	Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.	Diphosphonates	127-141	BCL6 transcription repressor	Homo sapiens	62-66
30210134-0	2019	Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements.	Cisplatin	32-41	BCL6 transcription repressor	Homo sapiens	138-142
30348636-8	2019	Moreover, in these follicular lymphoma cells, pan-HDAC inhibitor, vorinostat, restored their PRDM1 response to IL21 by lowering BCL6 bound to PRDM1.	Vorinostat	66-76	BCL6 transcription repressor	Homo sapiens	128-132
30805081-8	2019	BCL6 overexpression attenuated while BCL6 knockdown enhanced the Ang II-induced upregulation of NADPH oxidase 4 (NOX4), production of reactive oxygen species (ROS), and proliferation of VSMCs.	Reactive Oxygen Species	134-157	BCL6 transcription repressor	Homo sapiens	37-41
30805081-8	2019	BCL6 overexpression attenuated while BCL6 knockdown enhanced the Ang II-induced upregulation of NADPH oxidase 4 (NOX4), production of reactive oxygen species (ROS), and proliferation of VSMCs.	Reactive Oxygen Species	159-162	BCL6 transcription repressor	Homo sapiens	37-41
30805081-8	2019	BCL6 overexpression attenuated while BCL6 knockdown enhanced the Ang II-induced upregulation of NADPH oxidase 4 (NOX4), production of reactive oxygen species (ROS), and proliferation of VSMCs.	vsmcs	186-191	BCL6 transcription repressor	Homo sapiens	37-41
30805081-10	2019	BCL6 overexpression in SHR reduced NOX4 expression, ROS production, and proliferation of the aortic media of SHR.	Reactive Oxygen Species	52-55	BCL6 transcription repressor	Homo sapiens	0-4
30333862-0	2018	miR-339-5p inhibits lung adenocarcinoma invasion and migration by directly targeting BCL6.	mir-339-5p	0-10	BCL6 transcription repressor	Homo sapiens	85-89
30409904-3	2019	Here, using Bcl6 -/- knockout mice, HEK293A and HCT116 p53 -/- cells, and site-directed mutagenesis, we found that BCL6 interacts with p53 and thereby inhibits acetylation of Lys-132 in p53 by E1A-binding protein p300 (p300), a modification that normally occurs upon DNA damage-induced cellular stress and whose abrogation by BCL6 diminished transcriptional activation of p53 target genes, including that encoding caspase-1.	Lysine	175-178	BCL6 transcription repressor	Homo sapiens	115-119
30082494-4	2018	PRMT5 contributes to GC formation and affinity maturation at least in part through its direct interaction with and methylation of BCL6 at arginine 305 (R305), a modification necessary for the full transcriptional repressive effects of BCL6.	Arginine	138-146	BCL6 transcription repressor	Homo sapiens	130-134
30082494-4	2018	PRMT5 contributes to GC formation and affinity maturation at least in part through its direct interaction with and methylation of BCL6 at arginine 305 (R305), a modification necessary for the full transcriptional repressive effects of BCL6.	Arginine	138-146	BCL6 transcription repressor	Homo sapiens	235-239
30318011-0	2019	Combination Treatment of p53-Null HL-60 cells with Histone Deacetylase Inhibitors and Chlorambucil Augments Apoptosis and Increases BCL6 and p21 Gene Expression.	Chlorambucil	86-98	BCL6 transcription repressor	Homo sapiens	132-136
30318011-10	2019	CONCLUSION: The combination treatment of p53-null HL-60 cells with DNA-damaging agent CLB and HDACIs NaBu and TSA triggered additive to synergistic effects on apoptosis and upregulated BCL6 and p21 expression.	sethoxydim	101-105	BCL6 transcription repressor	Homo sapiens	185-189
30318011-10	2019	CONCLUSION: The combination treatment of p53-null HL-60 cells with DNA-damaging agent CLB and HDACIs NaBu and TSA triggered additive to synergistic effects on apoptosis and upregulated BCL6 and p21 expression.	trichostatin A	110-113	BCL6 transcription repressor	Homo sapiens	185-189
30333862-9	2018	In conclusion, the present data identified miR-339-5p as a novel LA suppressor which exerted its functions partly by negatively regulating BCL6.	mir-339-5p	43-53	BCL6 transcription repressor	Homo sapiens	139-143
29853448-9	2018	After IL-12 stimulation, both STAT1 and STAT4 directly bound on BCL6 and TBX21 gene loci accompanied by suppression of repressive histone mark trimethylated histone 3 lysine 27.	Lysine	167-173	BCL6 transcription repressor	Homo sapiens	64-68
30420967-9	2018	The suppression of BCL6 could increase chemosensitivity of U87 and U251 to temozolomide.	Temozolomide	75-87	BCL6 transcription repressor	Homo sapiens	19-23
30323893-8	2018	DH-My6 is a new well-validated MYC/BCL6 DHL cell line that will provide a useful model for studies of the pathogenesis and therapeutics for the less common DHL tumor type.	dh-my6	0-6	BCL6 transcription repressor	Homo sapiens	35-39
29434966-8	2018	miR-339-5p may inhibit lung cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition via BCL6 in vitro.	mir-339-5p	0-10	BCL6 transcription repressor	Homo sapiens	122-126
30178847-0	2018	BCL6 promotes the methotrexate-resistance by upregulating ZEB1 expression in children with acute B lymphocytic leukemia.	Methotrexate	18-30	BCL6 transcription repressor	Homo sapiens	0-4
30178847-1	2018	OBJECTIVE: To investigate the effect of BCL6 on methotrexate-resistant children with acute B lymphoblastic leukemia (B-ALL) and its underlying mechanism.	Methotrexate	48-60	BCL6 transcription repressor	Homo sapiens	40-44
30178847-5	2018	Cell cycle and apoptosis of methotrexate-resistant B-ALL cells (BALL-1/MTXR cells) were detected after overexpression or inhibition of BCL6, respectively.	Methotrexate	28-40	BCL6 transcription repressor	Homo sapiens	135-139
30178847-8	2018	RESULTS: QRT-PCR showed a higher BCL6 expression in bone marrow samples of methotrexate-resistant group than that of the non-resistant group.	Methotrexate	75-87	BCL6 transcription repressor	Homo sapiens	33-37
30178847-13	2018	CONCLUSIONS: BCL6 is overexpressed in the bone marrow of methotrexate-resistant children with B-ALL, which is capable of attenuating the sensitivity of B-ALL to methotrexate via promoting ZEB1 expression.	Methotrexate	57-69	BCL6 transcription repressor	Homo sapiens	13-17
30178847-13	2018	CONCLUSIONS: BCL6 is overexpressed in the bone marrow of methotrexate-resistant children with B-ALL, which is capable of attenuating the sensitivity of B-ALL to methotrexate via promoting ZEB1 expression.	Methotrexate	161-173	BCL6 transcription repressor	Homo sapiens	13-17
29563292-8	2018	Induction of TFH from naive T cells by LAIV was shown in newly induced TFH expressing BCL6 and CD21, followed by the detection of anti-HA antibodies.	tfh	13-16	BCL6 transcription repressor	Homo sapiens	86-90
29563292-8	2018	Induction of TFH from naive T cells by LAIV was shown in newly induced TFH expressing BCL6 and CD21, followed by the detection of anti-HA antibodies.	laiv	39-43	BCL6 transcription repressor	Homo sapiens	86-90
29563292-10	2018	LAIV-induced TFH differentiation was inhibited by BCL6, interleukin-21 (IL-21), ICOS, and CD40 signaling blocking, and that diminished anti-HA antibody production.	laiv	0-4	BCL6 transcription repressor	Homo sapiens	50-54
29563292-10	2018	LAIV-induced TFH differentiation was inhibited by BCL6, interleukin-21 (IL-21), ICOS, and CD40 signaling blocking, and that diminished anti-HA antibody production.	tfh	13-16	BCL6 transcription repressor	Homo sapiens	50-54
28929458-8	2018	Here we report near complete backbone 15N, 13C and 1H assignments for the BTB-POZ domain of BCL6 to assist in the analysis of binding modes for small molecules.	15n	38-41	BCL6 transcription repressor	Homo sapiens	92-96
28929458-8	2018	Here we report near complete backbone 15N, 13C and 1H assignments for the BTB-POZ domain of BCL6 to assist in the analysis of binding modes for small molecules.	13c	43-46	BCL6 transcription repressor	Homo sapiens	92-96
28929458-8	2018	Here we report near complete backbone 15N, 13C and 1H assignments for the BTB-POZ domain of BCL6 to assist in the analysis of binding modes for small molecules.	Hydrogen	51-53	BCL6 transcription repressor	Homo sapiens	92-96
28929458-8	2018	Here we report near complete backbone 15N, 13C and 1H assignments for the BTB-POZ domain of BCL6 to assist in the analysis of binding modes for small molecules.	btb	74-77	BCL6 transcription repressor	Homo sapiens	92-96
29487385-7	2018	These effects of ACY241 on antigen-specific memory T cells were associated with activation of downstream AKT/mTOR/p65 pathways and upregulation of transcription regulators including Bcl-6, Eomes, HIF-1 and T-bet.	Citarinostat	17-23	BCL6 transcription repressor	Homo sapiens	182-187
28589317-0	2017	Bcl6 gene-silencing facilitates PMA-induced megakaryocyte differentiation in K562 cells.	Tetradecanoylphorbol Acetate	32-35	BCL6 transcription repressor	Homo sapiens	0-4
29408811-5	2018	Lymph node biopsy in both cases on HE staining demonstrated vague nodularity readily highlighted by CD10, CD23, or BCL6.	Helium	35-37	BCL6 transcription repressor	Homo sapiens	115-119
27301994-0	2017	Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy.	Lenalidomide	112-124	BCL6 transcription repressor	Homo sapiens	68-72
27301994-4	2017	Here we present the first case, to our knowledge, of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma relapsing in the leptomeninges that achieved an outstanding durable remission with single-agent lenalidomide following salvage chemotherapy.	Lenalidomide	210-222	BCL6 transcription repressor	Homo sapiens	59-63
28589317-8	2017	Regarding these results, it might be concluded that Bcl6 knockdown combined with PMA therapy could present a new therapeutical strategy for refractory CML patients to imatinib.	Imatinib Mesylate	167-175	BCL6 transcription repressor	Homo sapiens	52-56
28410239-0	2017	Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.	Homoharringtonine	0-17	BCL6 transcription repressor	Homo sapiens	57-62
28760529-4	2017	Starting from high-throughput screening hits 1a and 2a, we identified a novel BCL6-corepressor interaction inhibitor 8c (cell-free enzyme-linked immunosorbent assay [ELISA] IC50=0.10microM, cell-based mammalian two-hybrid [M2H] assay IC50=0.72microM) by utilizing structure-based drug design (SBDD) based on an X-ray crystal structure of 1a bound to BCL6.	sbdd	293-297	BCL6 transcription repressor	Homo sapiens	78-82
28544233-4	2017	Here, we report that overexpression of BCL6 in a MM cell line, KMS12PE, induced transcriptional repression of ataxia telangiectasia mutated (ATM), a DDR signaling kinase, which was associated with a reduction in gammaH2AX formation after DNA damage.	gammah2ax	212-221	BCL6 transcription repressor	Homo sapiens	39-43
28714680-0	2017	Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.	pyrazolo(1,5-a)pyrimidine	27-52	BCL6 transcription repressor	Homo sapiens	53-70
28714680-0	2017	Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.	pyrazolo(1,5-a)pyrimidine	27-52	BCL6 transcription repressor	Homo sapiens	72-76
28711572-2	2017	DHL encompasses various histologies of lymphomas where the MYC oncogene and either BCL2 or BCL6 oncogenes are present concomitantly.	Cysteamine	0-3	BCL6 transcription repressor	Homo sapiens	91-95
28368400-0	2017	Interferon gamma is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.	Imatinib Mesylate	75-83	BCL6 transcription repressor	Homo sapiens	56-60
28368400-1	2017	B-cell CLL/lymphoma 6 (BCL6) exerts oncogenic effects in several human hematopoietic malignancies including chronic myeloid leukemia (CML), where BCL6 expression was shown to be essential for CML stem cell survival and self-renewal during imatinib mesylate (IM) treatment.	Imatinib Mesylate	239-256	BCL6 transcription repressor	Homo sapiens	0-21
28368400-1	2017	B-cell CLL/lymphoma 6 (BCL6) exerts oncogenic effects in several human hematopoietic malignancies including chronic myeloid leukemia (CML), where BCL6 expression was shown to be essential for CML stem cell survival and self-renewal during imatinib mesylate (IM) treatment.	Imatinib Mesylate	239-256	BCL6 transcription repressor	Homo sapiens	23-27
28368400-1	2017	B-cell CLL/lymphoma 6 (BCL6) exerts oncogenic effects in several human hematopoietic malignancies including chronic myeloid leukemia (CML), where BCL6 expression was shown to be essential for CML stem cell survival and self-renewal during imatinib mesylate (IM) treatment.	Imatinib Mesylate	239-256	BCL6 transcription repressor	Homo sapiens	146-150
28754906-0	2017	KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance.	Progesterone	103-115	BCL6 transcription repressor	Homo sapiens	45-49
28410239-0	2017	Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.	Imatinib Mesylate	29-37	BCL6 transcription repressor	Homo sapiens	57-62
28061782-5	2017	RESULTS: Three cases of DHL were detected: two with translocations of MYC and BCL2 and one with translocations of MYC and BCL6, all leading to death in less than six months.	Cysteamine	24-27	BCL6 transcription repressor	Homo sapiens	122-126
28485934-0	2017	Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.	pyrazolo(1,5-a)pyrimidine	13-38	BCL6 transcription repressor	Homo sapiens	39-56
28485934-0	2017	Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.	pyrazolo(1,5-a)pyrimidine	13-38	BCL6 transcription repressor	Homo sapiens	58-62
28485934-2	2017	We identified a pyrazolo[1,5-a]pyrimidine series of BCL6 binders from a fragment screen in parallel with a virtual screen.	pyrazolo(1,5-a)pyrimidine	16-41	BCL6 transcription repressor	Homo sapiens	52-56
28315684-0	2017	BCL6 mediates the effects of Gastrodin on promoting M2-like macrophage polarization and protecting against oxidative stress-induced apoptosis and cell death in macrophages.	gastrodin	29-38	BCL6 transcription repressor	Homo sapiens	0-4
28315684-7	2017	Moreover, we demonstrated that Gastrodin not only stimulated polarization toward M2-like macrophages, which promote tissue repair, but also rescued macrophages from oxidative stress, apoptosis and death by inducing BCL6 expression.	gastrodin	31-40	BCL6 transcription repressor	Homo sapiens	215-219
27856253-3	2017	Here we report a novel BCL6 inhibitory peptide, F1324 (Ac-LWYTDIRMSWRVP-OH), which we discovered using phage display technology; we also discuss this peptide"s structure-activity relationship (SAR).	f1324	48-53	BCL6 transcription repressor	Homo sapiens	23-27
27856253-8	2017	In addition, subsequent single-crystal X-ray diffraction analysis of F1324/BCL6(5-129) complex revealed that the high affinity of F1324 was caused by effective interaction of its side chains while its main chain structure was similar to that of BcoR(Arg498-514Pro).	f1324	69-74	BCL6 transcription repressor	Homo sapiens	75-79
27898346-4	2017	Similar to GD, the glucose analog 2-deoxyglucose (2DG) inhibits glycolysis, and 2DG induced Bcl6 expression in activated CD4 T cells.	Deoxyglucose	80-83	BCL6 transcription repressor	Homo sapiens	92-96
27898346-5	2017	The metabolic sensor AMP kinase (AMPK) is activated when glycolysis is decreased, and the induction of Bcl6 by GD was inhibited by the AMPK antagonist compound C. Additionally, activation of AMPK by the drug AICAR caused Bcl6 up-regulation in activated CD4 T cells.	Gadolinium	111-113	BCL6 transcription repressor	Homo sapiens	103-107
27898346-5	2017	The metabolic sensor AMP kinase (AMPK) is activated when glycolysis is decreased, and the induction of Bcl6 by GD was inhibited by the AMPK antagonist compound C. Additionally, activation of AMPK by the drug AICAR caused Bcl6 up-regulation in activated CD4 T cells.	Gadolinium	111-113	BCL6 transcription repressor	Homo sapiens	221-225
28955982-7	2016	PPARbeta/delta activation induced expression of several anti-inflammatory genes in a dose-dependent manner, and GW501516 inhibited Mcp1 promoter-driven luciferase in a BCL6-dependent manner.	GW 501516	112-120	BCL6 transcription repressor	Homo sapiens	168-172
28766546-5	2017	The paper describes a case of DHL with concomitant c-MYC and BCL6 gene rearrangements, which mimics diffuse large B-cell lymphoma, leg-type.	Cysteamine	30-33	BCL6 transcription repressor	Homo sapiens	61-65
27240592-8	2016	Finally, BCL6 and Lewis Y antigen were validated at the protein level by immunohistochemistry in 103 paraffin-embedded ovarian cancer tissues.	Paraffin	101-109	BCL6 transcription repressor	Homo sapiens	9-13
27546522-0	2016	SHP-1 is directly activated by the aryl hydrocarbon receptor and regulates BCL-6 in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).	Polychlorinated Dibenzodioxins	100-135	BCL6 transcription repressor	Homo sapiens	75-80
27546522-0	2016	SHP-1 is directly activated by the aryl hydrocarbon receptor and regulates BCL-6 in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).	Polychlorinated Dibenzodioxins	137-141	BCL6 transcription repressor	Homo sapiens	75-80
27546522-8	2016	We have shown that BCL-6 regulates B cell activation by repressing activation marker CD80 in the presence of TCDD.	Polychlorinated Dibenzodioxins	109-113	BCL6 transcription repressor	Homo sapiens	19-24
27546522-9	2016	TCDD-treatment led to a significant increase in the double positive (SHP-1hi BCL-6hi) population.	Polychlorinated Dibenzodioxins	0-4	BCL6 transcription repressor	Homo sapiens	77-82
27546522-11	2016	Collectively, these results suggest that SHP-1 is regulated by AHR in the presence of TCDD and may, in part through BCL-6, regulate TCDD-mediated suppression of human B cell activation.	Polychlorinated Dibenzodioxins	132-136	BCL6 transcription repressor	Homo sapiens	116-121
27546026-7	2016	For the HbSS group, when compared to the control group, the following genes showed differential expression: IL1RAP (2.76-fold), BCL6 (4.49-fold), CXCL10 (-2.12-fold), CXCR1 (-3.66-fold), and C3 (-2.0-fold).	hbss	8-12	BCL6 transcription repressor	Homo sapiens	128-132
26553360-0	2016	miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6.	339-5p	4-10	BCL6 transcription repressor	Homo sapiens	95-99
27268052-2	2016	Lestaurtinib, a JAK2 inhibitor and one of the hits from the screen, repressed survival of BCL6-deficient cells in vitro and reduced growth and proliferation of xenografts in vivo BCL6 deficiency in DG75-AB7 induced JAK2 mRNA and protein expression and STAT3 phosphorylation.	lestaurtinib	0-12	BCL6 transcription repressor	Homo sapiens	90-94
27268052-2	2016	Lestaurtinib, a JAK2 inhibitor and one of the hits from the screen, repressed survival of BCL6-deficient cells in vitro and reduced growth and proliferation of xenografts in vivo BCL6 deficiency in DG75-AB7 induced JAK2 mRNA and protein expression and STAT3 phosphorylation.	lestaurtinib	0-12	BCL6 transcription repressor	Homo sapiens	179-183
27103744-10	2016	However, cotreatment with ATRA reduces Bcl6 expression to baseline levels through suppression of interleukin-6 receptor signaling.	Tretinoin	26-30	BCL6 transcription repressor	Homo sapiens	39-43
27129176-11	2016	We concluded that the addition of thalidomide to the CHOP regimen significantly improved the CRR and showed a trend of improving clinical outcome in patients with DLBCL, especially for patients with Bcl-2 positive and Bcl-6 negative B-cell phenotype, without increased toxicity.	Thalidomide	34-45	BCL6 transcription repressor	Homo sapiens	218-223
26876184-4	2016	With consensus sequences being different from those in Th9, B cells, and macrophages, Bcl6 binding in Tfh cell was closely associated with a decrease in 5-hydroxymethylcytosine (5hmC).	5-hydroxymethylcytosine	153-176	BCL6 transcription repressor	Homo sapiens	86-90
26096934-0	2016	Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.	Steroids	0-7	BCL6 transcription repressor	Homo sapiens	122-126
26096934-7	2016	Upregulation of CK5-positive cells by 3-ketosteroids required induction of the transcriptional repressor BCL6 based on suppression of BCL6 by two independent BCL6 small hairpin RNAs or by prolactin.	3-ketosteroids	38-52	BCL6 transcription repressor	Homo sapiens	105-109
26096934-7	2016	Upregulation of CK5-positive cells by 3-ketosteroids required induction of the transcriptional repressor BCL6 based on suppression of BCL6 by two independent BCL6 small hairpin RNAs or by prolactin.	3-ketosteroids	38-52	BCL6 transcription repressor	Homo sapiens	134-138
26096934-7	2016	Upregulation of CK5-positive cells by 3-ketosteroids required induction of the transcriptional repressor BCL6 based on suppression of BCL6 by two independent BCL6 small hairpin RNAs or by prolactin.	3-ketosteroids	38-52	BCL6 transcription repressor	Homo sapiens	134-138
26876184-4	2016	With consensus sequences being different from those in Th9, B cells, and macrophages, Bcl6 binding in Tfh cell was closely associated with a decrease in 5-hydroxymethylcytosine (5hmC).	5-hydroxymethylcytosine	178-182	BCL6 transcription repressor	Homo sapiens	86-90
25543051-0	2015	Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves altered regulation of B cell lymphoma-6.	Polychlorinated Dibenzodioxins	42-77	BCL6 transcription repressor	Homo sapiens	109-126
26162096-6	2015	Furthermore, although the expression of the transcriptional repressor B-cell lymphoma-6 protein (BCL-6) was markedly enhanced by phenformin and AICAR, the repression of sPLA2 gene occurs through a mechanism independent of BCL-6 DNA binding site.	Phenformin	129-139	BCL6 transcription repressor	Homo sapiens	97-102
25957170-5	2015	In this article, we demonstrate, using a mutant form of Bcl6 with two BTB (bric-a-brac, tramtrack, broad-complex) mutations that abrogate corepressor binding, that the Bcl6 BTB domain is required for proper differentiation of Tfh and GC-Tfh cells in vivo.	btb	70-73	BCL6 transcription repressor	Homo sapiens	56-60
25957170-5	2015	In this article, we demonstrate, using a mutant form of Bcl6 with two BTB (bric-a-brac, tramtrack, broad-complex) mutations that abrogate corepressor binding, that the Bcl6 BTB domain is required for proper differentiation of Tfh and GC-Tfh cells in vivo.	btb	70-73	BCL6 transcription repressor	Homo sapiens	168-172
26657288-6	2016	Moreover, in DLBCL cells initially resistant to BH3 mimetic drugs, BCL6 inhibition induces a newly developed reliance on anti-apoptotic BCL2-family members for survival that translates in acquired susceptibility to BH3 mimetic drugs ABT-737 and obatoclax.	BH 3	48-51	BCL6 transcription repressor	Homo sapiens	67-71
26657288-6	2016	Moreover, in DLBCL cells initially resistant to BH3 mimetic drugs, BCL6 inhibition induces a newly developed reliance on anti-apoptotic BCL2-family members for survival that translates in acquired susceptibility to BH3 mimetic drugs ABT-737 and obatoclax.	BH 3	215-218	BCL6 transcription repressor	Homo sapiens	67-71
26657288-6	2016	Moreover, in DLBCL cells initially resistant to BH3 mimetic drugs, BCL6 inhibition induces a newly developed reliance on anti-apoptotic BCL2-family members for survival that translates in acquired susceptibility to BH3 mimetic drugs ABT-737 and obatoclax.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	233-236	BCL6 transcription repressor	Homo sapiens	67-71
26657288-7	2016	In germinal center B cell-like (GCB)-DLBCL cells, the proteasome inhibitor bortezomib and the NEDD inhibitor MLN4924 post-transcriptionally activated the BH3-only sensitizer NOXA thus counteracting the oncogenic switch to BCL2 induced by BCL6-targeting.	Bortezomib	75-85	BCL6 transcription repressor	Homo sapiens	238-242
26308950-5	2015	The ABCG1 and BCL6 gene was found in several triglyceride-related pathways (empirical P&lt;0.05), which were also replicated by ICSNPathway (empirical P&lt;0.05, FDR&lt;0.05).	Triglycerides	45-57	BCL6 transcription repressor	Homo sapiens	14-18
26308950-8	2015	Our study suggested that vitamin anabolism pathway, BCL6 gene pathways and ASTN2 gene may contribute to the genetic variation of plasma triglyceride concentrations.	Triglycerides	136-148	BCL6 transcription repressor	Homo sapiens	52-56
25543051-4	2015	The present study extends these findings by identifying B cell lymphoma-6 [BCL-6] as a putative cellular target for deregulation by TCDD, which may contribute to suppression of B cell function as well as NHL.	Polychlorinated Dibenzodioxins	132-136	BCL6 transcription repressor	Homo sapiens	56-73
25543051-4	2015	The present study extends these findings by identifying B cell lymphoma-6 [BCL-6] as a putative cellular target for deregulation by TCDD, which may contribute to suppression of B cell function as well as NHL.	Polychlorinated Dibenzodioxins	132-136	BCL6 transcription repressor	Homo sapiens	75-80
25543051-6	2015	In the presence of TCDD, BCL-6 protein levels were elevated and concurrently the same population of cells with high BCL-6 levels showed decreased CD80 and CD69 expression indicative of impaired cellular activation.	Polychlorinated Dibenzodioxins	19-23	BCL6 transcription repressor	Homo sapiens	25-30
25543051-6	2015	In the presence of TCDD, BCL-6 protein levels were elevated and concurrently the same population of cells with high BCL-6 levels showed decreased CD80 and CD69 expression indicative of impaired cellular activation.	Polychlorinated Dibenzodioxins	19-23	BCL6 transcription repressor	Homo sapiens	116-121
25543051-8	2015	Furthermore, a small molecule inhibitor of BCL-6 activity reversed TCDD-mediated suppression of CD80 expression in human B cells.	Polychlorinated Dibenzodioxins	67-71	BCL6 transcription repressor	Homo sapiens	43-48
25543051-10	2015	These results provide new mechanistic insights into the role of BCL-6 in the suppression of human B cell activation by TCDD.	Polychlorinated Dibenzodioxins	119-123	BCL6 transcription repressor	Homo sapiens	64-69
26185770-7	2015	ARACNE algorithm indicated a direct regulation of IFI16 by BCL6, STAT5B, and RELB, whereas the relationship between IFI16 and the other factors is modulated by intermediate factors.	aracne	0-6	BCL6 transcription repressor	Homo sapiens	59-63
25923331-8	2015	RNA transcriptome analyses post MS-275 and/or AZA treatment identified novel regulated candidate genes (up: BCL6, Hes2; down: FAIM, MLKL), which were specifically associated with the treatment responses of esophageal cancer cells.	Azacitidine	46-49	BCL6 transcription repressor	Homo sapiens	108-112
25482012-0	2015	The transcriptional regulator BCL6 participates in the secondary gene regulatory response to vitamin D.	Vitamin D	93-102	BCL6 transcription repressor	Homo sapiens	30-34
25482012-5	2015	We found BCL6 being most responsive to 1,25(OH)2D3 and selected it for further analysis.	Calcitriol	39-50	BCL6 transcription repressor	Homo sapiens	9-13
25295537-4	2014	PELI1 directly interacted with the oncoprotein B cell chronic lymphocytic leukemia (BCL6) and induced lysine 63-mediated BCL6 polyubiquitination.	Lysine	102-108	BCL6 transcription repressor	Homo sapiens	121-125
25628935-10	2015	Higher expression of BCL6 led to a significantly poorer DSS and DFS and multivariate analysis revealed that BCL6 was an independent risk factor of DSS and DFS.	dss	56-59	BCL6 transcription repressor	Homo sapiens	21-25
25628935-10	2015	Higher expression of BCL6 led to a significantly poorer DSS and DFS and multivariate analysis revealed that BCL6 was an independent risk factor of DSS and DFS.	dss	147-150	BCL6 transcription repressor	Homo sapiens	21-25
25628935-10	2015	Higher expression of BCL6 led to a significantly poorer DSS and DFS and multivariate analysis revealed that BCL6 was an independent risk factor of DSS and DFS.	dss	147-150	BCL6 transcription repressor	Homo sapiens	108-112
25394195-8	2014	However, the immunophenotypes of the LP-like cells resembled those of Hodgkin/Reed-Sternberg cells of CHL; they were positive for CD15, CD30, and PAX5, and negative for CD20, Bcl6, Oct2, and Bob1.	leucylproline	37-39	BCL6 transcription repressor	Homo sapiens	175-179
25232813-0	2014	Bcl-6 gets T cells off the sugar.	Sugars	27-32	BCL6 transcription repressor	Homo sapiens	0-5
25280001-6	2014	In addition, the NFkappaB inhibitor 6-Amino-4-(4-phenoxyphenethylamino)quinazoline, which reversed the anti-apoptotic effect of IL-4, preferentially blocked the response of genes positively correlated with ZAP-70 (e.g. CCR2, SUSD2), but enhanced the response of genes negatively correlated with ZAP-70 (e.g. AUH, BCL6, LY75, NFIL3).	6-amino-4-(4-phenoxyphenethylamino)quinazoline	36-82	BCL6 transcription repressor	Homo sapiens	313-317
25038272-3	2014	In this study we investigated Bcl-6 translocation and its transcriptional and translational levels in formalin-fixed, paraffin-embedded cerebral tissue sections from glioblastoma (GBM), low-grade glioma (Astrocytoma grade II and III), and meningioma patients, and correlated them with apoptotic processes and p53 and caspase-3 expression.	Formaldehyde	102-110	BCL6 transcription repressor	Homo sapiens	30-35
25038272-3	2014	In this study we investigated Bcl-6 translocation and its transcriptional and translational levels in formalin-fixed, paraffin-embedded cerebral tissue sections from glioblastoma (GBM), low-grade glioma (Astrocytoma grade II and III), and meningioma patients, and correlated them with apoptotic processes and p53 and caspase-3 expression.	Paraffin	118-126	BCL6 transcription repressor	Homo sapiens	30-35
24595451-0	2014	The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.	Rifabutin	4-13	BCL6 transcription repressor	Homo sapiens	49-53
25245533-3	2014	In this study, we showed that PMA induces an interaction between IL-32alpha, PKCepsilon, and BCL6, forming a trimer.	Tetradecanoylphorbol Acetate	30-33	BCL6 transcription repressor	Homo sapiens	93-97
25245533-7	2014	Further, the pan-PKC inhibitor and PKCepsilon inhibitor disrupted PMA-induced interaction between IL-32alpha and BCL6.	Tetradecanoylphorbol Acetate	66-69	BCL6 transcription repressor	Homo sapiens	113-117
25245533-9	2014	PMA induces post-translational modification of BCL6 by conjugation to SUMO-2, while IL-32alpha inhibits.	Tetradecanoylphorbol Acetate	0-3	BCL6 transcription repressor	Homo sapiens	47-51
25245533-10	2014	PKCepsilon inhibition eliminated PMA-induced SUMOylation of BCL6.	Tetradecanoylphorbol Acetate	33-36	BCL6 transcription repressor	Homo sapiens	60-64
24913620-11	2014	Transcription factors relevant to B cell differentiation, Bcl-6 and PAX5, as well as the protein kinase STAT3 pathway were involved in the inhibition of IL-6-induced IgM by SR144528.	SR 144528	173-181	BCL6 transcription repressor	Homo sapiens	58-63
24571259-6	2014	Further research is needed to elucidate the function of BCL6 and LMO2 in PCNSL.	pcnsl	73-78	BCL6 transcription repressor	Homo sapiens	56-60
24793055-6	2014	Particularly SER(11) seems to have a high relevance as it establishes specific bonds with BCL6(BTB) and is one of the only two residues sequence equivalent for the three studied corepressors.	Serine	13-16	BCL6 transcription repressor	Homo sapiens	90-99
24502926-8	2014	Furthermore, BMSCs elevated proto-oncogene BCL6 expression in the CML cells in response to imatinib treatment, suggesting the possible role of BCL6 in stroma-mediated TKI resistance.	Imatinib Mesylate	91-99	BCL6 transcription repressor	Homo sapiens	43-47
24502926-8	2014	Furthermore, BMSCs elevated proto-oncogene BCL6 expression in the CML cells in response to imatinib treatment, suggesting the possible role of BCL6 in stroma-mediated TKI resistance.	Imatinib Mesylate	91-99	BCL6 transcription repressor	Homo sapiens	143-147
24502926-9	2014	BKT140 reversed the protective effect of the stroma, effectively promoted apoptosis, and decreased BCL6 levels in CML cells cocultured with BMSCs.	BKT140	0-6	BCL6 transcription repressor	Homo sapiens	99-103
24595451-7	2014	An X-ray crystal structure of the rifabutin-BCL6 complex revealed that rifabutin occupies a partly non-polar pocket making interactions with tyrosine58, asparagine21 and arginine24 of the BCL6-POZ domain.	arginine24	170-180	BCL6 transcription repressor	Homo sapiens	44-48
24595451-7	2014	An X-ray crystal structure of the rifabutin-BCL6 complex revealed that rifabutin occupies a partly non-polar pocket making interactions with tyrosine58, asparagine21 and arginine24 of the BCL6-POZ domain.	arginine24	170-180	BCL6 transcription repressor	Homo sapiens	188-192
25130812-1	2014	This study was aimed to investigate the anti-proliferative effect of genistein (Gen) on BCL-6 positive Raji cells and its related mechanism.	Genistein	69-78	BCL6 transcription repressor	Homo sapiens	88-93
24878528-0	2014	High concentrations of glucose suppress etoposide-induced cell death of B-cell lymphoma through BCL-6.	Glucose	23-30	BCL6 transcription repressor	Homo sapiens	96-101
24878528-0	2014	High concentrations of glucose suppress etoposide-induced cell death of B-cell lymphoma through BCL-6.	Etoposide	40-49	BCL6 transcription repressor	Homo sapiens	96-101
24878528-2	2014	In this study we investigated the expression of the glucose induced transcription factor Bcl-6 and the underlying mechanism by which it suppresses B-cell lymphoma cell death.	Glucose	52-59	BCL6 transcription repressor	Homo sapiens	89-94
24878528-4	2014	BCL-6 expression was induced by glucose but down-regulated by etoposide.	Glucose	32-39	BCL6 transcription repressor	Homo sapiens	0-5
24878528-4	2014	BCL-6 expression was induced by glucose but down-regulated by etoposide.	Etoposide	62-71	BCL6 transcription repressor	Homo sapiens	0-5
24878528-6	2014	The molecular mechanism by which glucose prevented etoposide-induced tumor cell death was shown to involve the BCL-6 mediated caspase pathway.	Glucose	33-40	BCL6 transcription repressor	Homo sapiens	111-116
24878528-6	2014	The molecular mechanism by which glucose prevented etoposide-induced tumor cell death was shown to involve the BCL-6 mediated caspase pathway.	Etoposide	51-60	BCL6 transcription repressor	Homo sapiens	111-116
24878528-7	2014	Our data suggest that glucose-induced BCL-6 overexpression could abrogate the etoposide chemotherapy effect on tumor cell death.	Glucose	22-29	BCL6 transcription repressor	Homo sapiens	38-43
24878528-7	2014	Our data suggest that glucose-induced BCL-6 overexpression could abrogate the etoposide chemotherapy effect on tumor cell death.	Etoposide	78-87	BCL6 transcription repressor	Homo sapiens	38-43
24595451-0	2014	The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.	Rifabutin	4-13	BCL6 transcription repressor	Homo sapiens	110-114
24595451-0	2014	The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.	rifamycin SV	26-38	BCL6 transcription repressor	Homo sapiens	49-53
24595451-0	2014	The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.	rifamycin SV	26-38	BCL6 transcription repressor	Homo sapiens	110-114
24595451-5	2014	The ansamycin antibiotic, rifamycin SV, inhibited BCL6 transcriptional repression and NMR spectroscopy confirmed a direct interaction between rifamycin SV and BCL6.	Rifabutin	4-13	BCL6 transcription repressor	Homo sapiens	50-54
24595451-5	2014	The ansamycin antibiotic, rifamycin SV, inhibited BCL6 transcriptional repression and NMR spectroscopy confirmed a direct interaction between rifamycin SV and BCL6.	Rifabutin	4-13	BCL6 transcription repressor	Homo sapiens	159-163
24595451-5	2014	The ansamycin antibiotic, rifamycin SV, inhibited BCL6 transcriptional repression and NMR spectroscopy confirmed a direct interaction between rifamycin SV and BCL6.	rifamycin SV	26-35	BCL6 transcription repressor	Homo sapiens	50-54
24595451-5	2014	The ansamycin antibiotic, rifamycin SV, inhibited BCL6 transcriptional repression and NMR spectroscopy confirmed a direct interaction between rifamycin SV and BCL6.	rifamycin SV	26-35	BCL6 transcription repressor	Homo sapiens	159-163
24595451-5	2014	The ansamycin antibiotic, rifamycin SV, inhibited BCL6 transcriptional repression and NMR spectroscopy confirmed a direct interaction between rifamycin SV and BCL6.	rifamycin SV	142-151	BCL6 transcription repressor	Homo sapiens	159-163
24595451-7	2014	An X-ray crystal structure of the rifabutin-BCL6 complex revealed that rifabutin occupies a partly non-polar pocket making interactions with tyrosine58, asparagine21 and arginine24 of the BCL6-POZ domain.	tyrosine58	141-151	BCL6 transcription repressor	Homo sapiens	44-48
24595451-7	2014	An X-ray crystal structure of the rifabutin-BCL6 complex revealed that rifabutin occupies a partly non-polar pocket making interactions with tyrosine58, asparagine21 and arginine24 of the BCL6-POZ domain.	asparagine21	153-165	BCL6 transcription repressor	Homo sapiens	44-48
23382195-4	2013	Analysis of the PARP-1 primary sequence suggested that phosphorylation of PARP-1 Serine 177 (Ser-177) by AMP-activated protein kinase (AMPK) is responsible for the induction of Bcl-6.	Serine	81-87	BCL6 transcription repressor	Homo sapiens	177-182
23927977-12	2013	CONCLUSION: In this retrospective study with heterogeneous treatment modality, we identified bcl-6 expression and elevated LDH level as two prognostic factors for PG-DLBCL.	pg-dlbcl	163-171	BCL6 transcription repressor	Homo sapiens	93-98
24114011-10	2014	Importantly, BCL6 overexpression in GBC was strongly associated with worse DSS (p &lt; 0.0001) and DFS (p &lt; 0.0001) in the univariate analysis, and remained independently predictive of adverse outcomes (p = 0.001, hazard ratio (H.R.)	dss	75-78	BCL6 transcription repressor	Homo sapiens	13-17
24114011-15	2014	BCL6 overexpression also independently predicts worse DSS and DFS, suggesting it has a role in tumorigenesis or carcinogenesis and could be a potential prognostic indicator in GBC.	dss	54-57	BCL6 transcription repressor	Homo sapiens	0-4
23382195-4	2013	Analysis of the PARP-1 primary sequence suggested that phosphorylation of PARP-1 Serine 177 (Ser-177) by AMP-activated protein kinase (AMPK) is responsible for the induction of Bcl-6.	Serine	81-84	BCL6 transcription repressor	Homo sapiens	177-182
23382195-5	2013	Our results show that AMPK activation with treatment of 5-aminoimidazole-4-carboxamide ribonucleotide, metformin, or pulsatile shear stress induces PARP-1 dissociation from the Bcl-6 intron 1, increases Bcl-6 expression, and inhibits expression of inflammatory mediators.	AICA ribonucleotide	56-101	BCL6 transcription repressor	Homo sapiens	177-182
23382195-5	2013	Our results show that AMPK activation with treatment of 5-aminoimidazole-4-carboxamide ribonucleotide, metformin, or pulsatile shear stress induces PARP-1 dissociation from the Bcl-6 intron 1, increases Bcl-6 expression, and inhibits expression of inflammatory mediators.	AICA ribonucleotide	56-101	BCL6 transcription repressor	Homo sapiens	203-208
23382195-5	2013	Our results show that AMPK activation with treatment of 5-aminoimidazole-4-carboxamide ribonucleotide, metformin, or pulsatile shear stress induces PARP-1 dissociation from the Bcl-6 intron 1, increases Bcl-6 expression, and inhibits expression of inflammatory mediators.	Metformin	103-112	BCL6 transcription repressor	Homo sapiens	177-182
23107779-8	2012	MLLr B-ALL featured prominent cytosine hypomethylation, which was linked with MLL fusion protein binding, H3K79 dimethylation, and transcriptional upregulation, affecting a set of known and newly identified MLL fusion direct targets with oncogenic activity such as FLT3 and BCL6.	Cytosine	30-38	BCL6 transcription repressor	Homo sapiens	274-278
23737761-6	2013	Through the use of short hairpin RNA inhibitors of PPARbeta/delta, BCL-6, and MMP-9, it was evident that PPARbeta/delta was responsible for the ligand-dependent effects whereas BCL-6 dissociation upon GW501516 treatment was ultimately responsible for decreasing MMP-9 expression and hence invasion activity.	GW 501516	201-209	BCL6 transcription repressor	Homo sapiens	177-182
22213394-0	2012	Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.	Cyclophosphamide	122-138	BCL6 transcription repressor	Homo sapiens	42-46
22213394-2	2012	The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases.	Cyclophosphamide	118-134	BCL6 transcription repressor	Homo sapiens	86-90
22213394-2	2012	The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases.	Doxorubicin	136-147	BCL6 transcription repressor	Homo sapiens	86-90
22213394-2	2012	The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases.	Vincristine	149-160	BCL6 transcription repressor	Homo sapiens	86-90
22213394-2	2012	The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases.	Prednisone	166-176	BCL6 transcription repressor	Homo sapiens	86-90